Thoracic cancer
MONDO:0003274A primary or metastatic malignant neoplasm affecting the tissues of the thorax.
Also known as: thoracic tumor, thoracic tumour, thorax neoplasm, tumor of thorax, tumour of thorax, cancer of thoracic segment of trunk, malignant neoplasm of the thorax, malignant neoplasm of thoracic segment of trunk
10075 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1227 trials in this tab.
-
Can a single shot build a cancer army inside the body?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests an experimental gene therapy called UB-VV400, designed to instruct a person's own cells to become CAR T cells that target CD22 on B-cell cancers. It is given together with rapamycin, a drug that may help the therapy work better. The study enrolls adults with rela…
Phase: PHASE1, PHASE2 • Sponsor: Umoja Biopharma • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 02:00 UTC
-
Can your own immune cells beat advanced cancer?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…
Phase: PHASE1, PHASE2 • Sponsor: Gritbio Medicine, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Can a pill restore the Body's tumor suppressor to fight multiple cancers?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…
Phase: PHASE1, PHASE2 • Sponsor: LG Chem • Aim: ⭐️ CURE ⭐️
Last updated Aug 09, 2026 00:00 UTC
-
Can your own immune cells fight advanced cancer?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…
Phase: PHASE1, PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 08, 2026 00:03 UTC
-
Can zapping tumors before surgery boost lung cancer treatment?
⭐️ CURE ⭐️ Not yet recruitingThis phase 2 trial is testing whether a three-pronged approach—tumor ablation, immunotherapy (tislelizumab), and chemotherapy—can improve outcomes for people with stage II-IIIB non-small cell lung cancer that can be surgically removed. The goal is to see if this combination can e…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: ⭐️ CURE ⭐️
Last updated Jul 29, 2026 00:00 UTC
-
Can a Pre-Surgery drug combo wipe out early lung cancer?
⭐️ CURE ⭐️ Not yet recruitingThis trial investigates whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery can completely eliminate tumors in people with early-stage non-small cell lung cancer (tumors 2 to 3.9 cm). Participants will receive three cycles of the drug combinat…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Ultra-Fast CAR-T cells aim to beat back tough lymphomas
⭐️ CURE ⭐️ Not yet recruitingThis phase 2 trial tests whether a new CAR-T cell therapy called UF-KURE19 can effectively treat adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The therapy is made from a patient's…
Phase: PHASE2 • Sponsor: Kure Cells, INC • Aim: ⭐️ CURE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
Can a new injection shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…
Phase: PHASE1, PHASE2 • Sponsor: Antares Therapeutics, Inc • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can Long-Term tucatinib use remain safe for HER2-Positive cancers?
Disease control Not yet recruitingThis study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…
Phase: PHASE4 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer
Disease control Not yet recruitingThis trial tests whether combining an EGFR-targeted pill (EGFR-TKI) with an antibody-drug conjugate (trastuzumab rezetecan) can shrink tumors in people with advanced non-small cell lung cancer that has both an EGFR mutation and HER2 alterations. Participants receive the combinati…
Phase: PHASE2 • Sponsor: Yongsheng Wang • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a Weight-Loss drug shield breast cancer Survivors' hearts?
Disease control Not yet recruitingThis trial tests whether adding semaglutide to structured lifestyle counseling improves heart and blood vessel health in postmenopausal breast cancer survivors with obesity who are taking an aromatase inhibitor. Participants will receive either semaglutide or a placebo, along wit…
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can Pre-Surgery rehab ease recovery from tumor bowel blockage?
Disease control Not yet recruitingThis trial tests whether a multimodal prehabilitation program—combining exercise, nutrition, and psychological support—can improve outcomes for patients with tumor-related bowel obstruction. Participants are randomly assigned to receive either this program plus postoperative immu…
Phase: NA • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Engineered immune cells take aim at deadly lung cancer
Disease control Not yet recruitingThis early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
Disease control Not yet recruitingThis phase 2 trial is testing a two-step treatment approach for people with advanced HER2-positive breast cancer. First, participants receive an induction therapy with trastuzumab rezetecan. If the disease does not progress, they then move to a maintenance phase combining trastuz…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
A shot at safer CAR t: early brain protection for lymphoma patients?
Disease control Not yet recruitingThis trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Lung cancer breakthrough: could observation replace surgery?
Disease control Not yet recruitingThis pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surger…
Phase: PHASE1 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
Disease control Not yet recruitingThis early-phase trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with immunotherapy and chemotherapy for advanced triple-negative breast cancer. The goal is to see if this multi-pronged approach can safely boo…
Phase: PHASE1, PHASE2 • Sponsor: BreakBio Corp • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Zapping resistant spots: radiation may buy more time for lung cancer patients on targeted drugs
Disease control Not yet recruitingThis study tests whether precisely targeted radiation (SBRT) can stop or slow the growth of a few resistant spots in metastatic lung cancer patients who are already on targeted therapy (TKI). About 60 adults with EGFR or ALK mutations will receive radiation to those spots, and do…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Two apps battle to help smokers kick the habit
Disease control Not yet recruitingThis study compares two smartphone apps designed to help people stop smoking. One app uses a therapy that focuses on mood and behavior, while the other uses standard quitting advice. About 1,800 adult smokers who want to quit in the next month will use one of the apps for 30 days…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Blood test may tailor lung cancer immunotherapy, sparing unnecessary treatment
Disease control Not yet recruitingThis trial is testing whether a blood test that detects cancer DNA can guide the use of durvalumab, an immunotherapy, after standard chemoradiotherapy in patients with stage III lung cancer that cannot be removed by surgery. The goal is to see if giving durvalumab only to patient…
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
A nudge in time: could text reminders boost alcohol care for cancer patients?
Disease control Not yet recruitingThis trial tests whether simple reminders—sent to patients' phones and to their care teams—can increase the use of alcohol screening and brief counseling (SBIRT) during cancer care. About 315 adults with cancer across four clinics will take part, with some clinics using the remin…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a drug combo outsmart a tough breast cancer subtype?
Disease control Not yet recruitingThis phase III trial is testing whether adding everolimus to trastuzumab rezetecan helps people with a specific subtype of triple-negative breast cancer (called luminal androgen receptor) live longer without their disease progressing. The study enrolls adults with advanced or met…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new Armpit-Incision technique make breast reconstruction safer and easier?
Disease control Not yet recruitingThis study compares two ways to rebuild a breast after a mastectomy for breast cancer: a newer, minimally invasive endoscopic method done through a small armpit incision, versus the traditional latissimus dorsi flap surgery (using muscle from the back, often with an implant). The…
Sponsor: Du Zhenggui • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Poop pills may help revive immunotherapy in lung cancer patients
Disease control Not yet recruitingThis study tests whether a fecal microbiota transplant (FMT) — transferring healthy gut bacteria from a donor — can help restore the immune system's ability to fight advanced non-small cell lung cancer in 15 patients whose disease worsened after prior immunotherapy. Participants …
Phase: PHASE2 • Sponsor: Se-Hoon Lee • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new drug combo outperform standard therapy for lung cancer?
Disease control Not yet recruitingThis phase 3 trial is testing whether an investigational drug called ABBV-1480, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced or metastatic squamous non-small cell lung cancer. Particip…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for lung cancer patients with lung scarring: trial tests safer treatments
Disease control Not yet recruitingThis study is for people with advanced non-small cell lung cancer who also have interstitial lung disease (ILD), a condition that causes lung scarring. Many doctors avoid treating these patients due to risks of worsening ILD. The trial will test a specific chemotherapy as first t…
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can less radiation be just as effective for early breast cancer?
Disease control Not yet recruitingThis trial is testing whether treating only part of the breast with radiation is as effective as treating the whole breast in women with early-stage, low-risk breast cancer. Participants are women aged 40 and older who had breast-conserving surgery and did not have a sentinel lym…
Phase: PHASE3 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
Disease control Not yet recruitingThis phase II trial is testing whether combining an experimental antibody called SSGJ-612 with a targeted chemotherapy (an antibody-drug conjugate) can shrink tumors in people with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer. The study enrolls ab…
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
PET scans may predict which breast cancer patients benefit from elacestrant
Disease control Not yet recruitingThis trial is testing whether a special PET scan can help predict how well the drug elacestrant works in people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has not responded to prior hormone therapy. All participants will take elacestrant daily…
Phase: PHASE2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new pill outperform chemotherapy for a Hard-to-Treat lung cancer mutation?
Disease control Not yet recruitingThis trial is testing whether an experimental oral drug, HS-10504, can slow the progression of advanced non-small cell lung cancer in people whose tumors carry a specific EGFR C797S mutation and have already failed prior EGFR inhibitor therapy. Participants will be randomly assig…
Phase: PHASE3 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can immune checkpoint drugs fight cancers beyond their approved uses?
Disease control Not yet recruitingThis phase 2 trial investigates whether immune checkpoint inhibitors—medicines that help the immune system attack cancer—can be effective when used off-label for different types of malignancies. Adults with cancer whose doctor is considering such treatment may join. Participants …
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
Disease control Not yet recruitingThis trial is testing an experimental drug called AMT-116 in people with advanced or metastatic non-squamous non-small cell lung cancer that has worsened after standard treatments. The study has two parts: the first compares two different doses of AMT-116 to see which works bette…
Phase: PHASE2, PHASE3 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can Gene-Edited immune cells tame Hard-to-Treat cancers?
Disease control Not yet recruitingThis trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostat…
Phase: PHASE1, PHASE2 • Sponsor: CoRegen, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Dual-Pronged antibody outsmart advanced cancers?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called SI-B036, a bispecific antibody designed to target cancer cells in people with locally advanced or metastatic breast cancer and other solid tumors. The study aims to find the safest dose and understand how the drug b…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug combo outsmart triple-negative breast cancer?
Disease control Not yet recruitingThis phase 2 trial is investigating whether adding an experimental drug called retlirafusp alfa to standard chemotherapy or to another drug called fuzuloparib can improve outcomes for people with triple-negative breast cancer (TNBC). The study includes two groups: one with early-…
Phase: PHASE2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
Disease control Not yet recruitingThis phase 2 trial tests whether the immunotherapy drug cemiplimab can be used alone before surgery for certain patients with early-stage non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if some patients can safely skip chemotherapy and its harsh side ef…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…
Phase: PHASE1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a drug duo outsmart ALK-Positive lung cancer?
Disease control Not yet recruitingThis trial is testing whether combining two targeted therapies—lorlatinib and sacituzumab tirumotecan—can better control advanced ALK-positive non-small cell lung cancer when used as the first treatment. The study involves about 153 adults with locally advanced or metastatic dise…
Phase: PHASE2 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New radiation drug targets tough cancers in early trial
Disease control Not yet recruitingThis early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a smart drug deliver a toxic payload directly to cancer cells?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…
Phase: PHASE1 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a breast cancer combo be safer for diabetics?
Disease control Not yet recruitingThis trial is testing whether a combination of drugs—inavolisib plus fulvestrant, with or without palbociclib—is safe for people with a specific type of advanced breast cancer (HR+, HER2-negative) that has a PIK3CA mutation, and who also have type 2 diabetes. The main focus is on…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Personalized cell therapy takes on Hard-to-Treat tumors
Disease control Not yet recruitingThis early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
Disease control Not yet recruitingThis phase 3 trial is testing whether giving four cycles of chemotherapy combined with targeted therapy (trastuzumab and pertuzumab) before surgery works as well as the standard six cycles for people with intermediate-risk HER2-positive breast cancer. The goal is to see if a shor…
Phase: PHASE3 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo aims to boost breast cancer remission before surgery
Disease control Not yet recruitingThis phase 3 trial tests whether a combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) works better than standard chemotherapy before surgery for stage II-III triple-negative breast cancer. About 765 participants will be enrolled. The study aims to improv…
Phase: PHASE3 • Sponsor: Women's Cancer Study Group GmbH • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental drug duo aims to boost immune attack on tough cancers
Disease control Not yet recruitingThis study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the tw…
Phase: PHASE1, PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could a probiotic boost breast cancer treatment? new trial aims to find out
Disease control Not yet recruitingThis Phase II trial will test whether adding a live biotherapeutic product called MO-03 (a type of probiotic) to standard chemotherapy and the immunotherapy drug pembrolizumab can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants will tak…
Phase: PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New endoscopic technique could simplify breast reconstruction after mastectomy
Disease control Not yet recruitingThis study will compare a newer, less invasive endoscopic breast reconstruction method (direct-to-implant) with traditional flap surgery (using tissue from the abdomen) in 588 women who had a mastectomy at least one year ago. The goal is to see if the endoscopic approach leads to…
Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Blood test may let cancer patients take safe breaks from immunotherapy
Disease control Not yet recruitingThis trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…
Phase: NA • Sponsor: Natera, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding an investigational drug called ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. Ivonescimab is a bispecific antibody that works in two ways: it helps the immune sys…
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug GEN1119 aims to fight solid tumors that resist standard care
Disease control Not yet recruitingThis trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Triple-Drug combo tackle breast cancer brain metastases?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding anlotinib to a combination of culmerciclib and endocrine therapy can control disease in people with HR-positive, HER2-negative breast cancer that has spread to the brain. The study enrolls adults with newly diagnosed or progressing bra…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a biomarker spare breast cancer patients from harsh chemo?
Disease control Not yet recruitingThis trial explores whether people with early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes (TILs) can safely skip a class of chemotherapy drugs called anthracyclines, which are effective but can harm the heart. Participants receive 12 week…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: drug combo targets resistant tumors
Disease control Not yet recruitingThis study tests a new drug, prifetrastat, combined with fulvestrant for people with advanced HR+/HER2- breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 51 participants will receive the combination to see if it can shrink tumors o…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart tough lung cancer?
Disease control Not yet recruitingThis phase II trial is testing whether combining an experimental drug called ALK201 with an existing immunotherapy, ivonescimab, can help people with advanced squamous non-small cell lung cancer. The study includes adults whose tumors have a specific marker (FGFR2b) and who have …
Phase: PHASE2 • Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a needle through the windpipe beat the knife for early lung cancer?
Disease control Not yet recruitingThis trial tests whether a minimally invasive procedure called bronchoscopic microwave ablation can be as effective as surgery for early-stage lung cancer (stage IA). The procedure uses a bronchoscope to guide a needle to the tumor and destroy it with heat, potentially preserving…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a genetic trait stop chemotherapy from working? a trial aims to fix that
Disease control Not yet recruitingThis trial is testing whether a new dosing algorithm can help people with a genetic trait called Duffy-null get the full benefit of chemotherapy. Many people of African or Middle Eastern descent naturally have lower white blood cell counts (Duffy-null neutropenia), which can lead…
Phase: PHASE1, PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New combo strategy takes on Hard-to-Treat breast cancer
Disease control Not yet recruitingThis phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low triple-negative breast cancer that has spread. About 260 participants will be randomly assigned to receive either the altern…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an experimental drug called DS-3939a in adults with advanced solid tumors, including a type of lung cancer. The study has two parts: the first checks safety and the best dose, and the second looks at whether the drug, alone or with other cancer treatments, c…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a targeted drug combo outperform standard chemo for tough lung cancer?
Disease control Not yet recruitingThis trial is testing whether a new experimental drug called YL201, when combined with the immunotherapy serplulimab, can help people with extensive-stage small cell lung cancer live longer compared to the current standard treatment (carboplatin and etoposide plus serplulimab). T…
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a targeted radiation boost slow advanced lung cancer?
Disease control Not yet recruitingThis trial is testing whether giving radiotherapy to the main lung tumour, in addition to standard chemotherapy or immunotherapy, can reduce cancer spread and help people with metastatic non-small-cell lung cancer live longer. Around 420 adults with newly diagnosed stage IV lung …
Phase: PHASE3 • Sponsor: Trans Tasman Radiation Oncology Group • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a novel drug combo outperform standard chemo for lung cancer?
Disease control Not yet recruitingThis trial is investigating whether a new combination of drugs—BL-B01D1 plus a PD-1/VEGF bispecific antibody—can work better than the current standard treatment (tislelizumab plus chemotherapy) for people with locally advanced or metastatic non-squamous non-small cell lung cancer…
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a novel drug combo outperform chemo in lung cancer?
Disease control Not yet recruitingThis trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy that targets PD-1 and VEGF, works better than standard chemotherapy combined with the same immunotherapy for people with advanced squamous non-small cell lung cancer. About 200 adults with th…
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Triple-Action antibody takes aim at advanced breast cancer
Disease control Not yet recruitingThis trial is testing an experimental drug called GB268, a tri-specific antibody that targets three key pathways involved in cancer growth. It is being studied alone or in combination with other treatments in people with locally advanced or metastatic breast cancer. The goal is t…
Phase: PHASE1, PHASE2 • Sponsor: Eddingpharm (Zhuhai) Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Ovarian suppression plus tamoxifen: a Long-Term bet against breast cancer recurrence
Disease control Not yet recruitingThis study follows young women with hormone-sensitive breast cancer who stayed premenopausal or resumed menstruation after chemotherapy. Researchers are investigating whether adding two years of ovarian function suppression to standard tamoxifen therapy can lower the chance of ca…
Sponsor: MedicalExcellence • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
A shield for bone marrow: can a drug stop Chemo's blood cell side effect?
Disease control Not yet recruitingThis trial tests whether a drug called trilaciclib can prevent myelosuppression — a drop in blood cell counts — caused by a type of chemotherapy known as topoisomerase I inhibitor antibody-drug conjugates (ADCs). About 96 cancer patients who are scheduled to receive these ADC dru…
Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can Real-Time MRI make radiation safer for Ultra-Central lung tumors?
Disease control Not yet recruitingThis trial tests whether MRI-guided stereotactic body radiotherapy (SBRT) can safely treat ultra-central lung tumors—growths located near the windpipe and major airways. Using an MR-LINAC machine, doctors can adjust the radiation beam in real time as the patient breathes, potenti…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Smart patch and app aim to boost lung recovery after cancer surgery
Disease control Not yet recruitingThis trial tests whether a wireless wearable monitor (chest patch or wristband) plus a smartphone-based rehab program can help people recover lung function after surgery for non-small cell lung cancer. Participants who have had curative-intent surgery will either receive standard…
Phase: NA • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a targeted drug plus immunotherapy outsmart tough breast cancer?
Disease control Not yet recruitingThis phase III trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy (PD-1 antibody), works better than standard chemotherapy plus immunotherapy for people with advanced triple-negative breast cancer that has a specific protein (PD-L1). The study inc…
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Experimental combo aims to tackle Treatment-Resistant cancers
Disease control Not yet recruitingThis early-stage trial tests whether an experimental drug called TLN-499, combined with the approved cancer drug venetoclax, is safe and tolerable for people with certain advanced solid tumors that have stopped responding to standard treatments. The study includes adults with sma…
Phase: PHASE1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a new drug ASP388B take on advanced solid tumors?
Disease control Not yet recruitingThis trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New cancer drug candidate SHR-4685 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a gentler drug trio tame small cell lung cancer in older patients?
Disease control Not yet recruitingThis trial is testing a combination of three drugs—benmelstobart, anlotinib, and etoposide—as a first treatment for elderly patients (65 and older) or those too frail for standard intensive chemotherapy. The goal is to see if this platinum-free regimen can control the cancer and …
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a smart drug deliver a toxic payload directly to cancer cells?
Disease control Not yet recruitingThis early-phase trial is testing an experimental antibody-drug conjugate called MC002 in adults with advanced solid tumors, such as esophageal or lung cancer, that have progressed after standard treatments. MC002 is designed to target a protein found on cancer cells and deliver …
Phase: PHASE1 • Sponsor: Hangzhou MacroLink Biopharmaceutical LLC • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a drug that blocks HER proteins re-sensitize resistant breast cancer to hormone therapy?
Disease control Not yet recruitingThis trial investigates whether adding neratinib, a drug that blocks HER2/3/4 proteins, to standard hormone therapy can improve disease control in people with metastatic ER+/HER2- breast cancer that has stopped responding to first-line endocrine therapy. Participants will receive…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Microwave ablation vs. radiotherapy: which Non-Surgical option works best for early lung cancer?
Disease control Not yet recruitingThis trial compares two treatments for early-stage lung cancer in patients who cannot have surgery: microwave ablation delivered through a bronchoscope versus standard stereotactic body radiotherapy. The goal is to see which approach better controls the tumor over two years, with…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a new drug outsmart resistant breast cancer?
Disease control Not yet recruitingThis phase II trial is testing an experimental drug called SMP-656 in people with HER2-positive breast cancer that has spread or cannot be removed and has worsened after prior treatment with a specific type of antibody-drug conjugate. The study aims to see if SMP-656 can shrink t…
Phase: PHASE2 • Sponsor: Chengdu SciMount Pharmatech Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Less radiation for breast cancer? a trial tests a smarter, response-based approach
Disease control Not yet recruitingThis trial is investigating whether women with node-positive breast cancer whose lymph nodes are cancer-free after chemotherapy can safely receive less extensive radiation. Instead of radiating the entire lymph node region, the study compares standard radiation to a more targeted…
Phase: NA • Sponsor: Aya Ahmed Sayed • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a nanoparticle deliver chemo more safely to Hard-to-Treat cancers?
Disease control Not yet recruitingThis trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…
Phase: PHASE1, PHASE2 • Sponsor: BrYet US, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a vaccine train the immune system to hunt down hidden breast cancer cells?
Disease control Not yet recruitingThis phase II trial is testing whether a vaccine called STEMVAC can help prevent triple-negative breast cancer from coming back after surgery. The vaccine targets proteins that cancer cells use to grow and spread, aiming to boost the immune system to destroy any remaining tumor c…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
Disease control Not yet recruitingThis phase 3 trial tests whether a single dose of SRG-514 (ketorolac), given directly into the area where a breast tumor is removed, can help prevent cancer from coming back. The study enrolls adults with stage II-III triple-negative breast cancer who are having breast-conserving…
Phase: PHASE3 • Sponsor: SURGE Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug sequence aims to outsmart advanced breast cancer
Disease control Not yet recruitingThis trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine thera…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
Disease control Not yet recruitingThis trial tests whether an online, personalized lifestyle program can help rural postmenopausal breast and endometrial cancer survivors lose weight and improve their health. Participants follow a tailored diet and aerobic exercise plan, with mobile health tools to track progress…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat solid tumors?
Disease control Not yet recruitingThis trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…
Phase: PHASE1, PHASE2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
Disease control Not yet recruitingThis early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…
Phase: PHASE1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New 'WARNING Pack' aims to protect quality of life in older cancer patients
Disease control Not yet recruitingThis trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…
Phase: NA • Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Radiation hotspots may boost lung cancer treatment — a trial puts it to the test
Disease control Not yet recruitingThis trial compares standard stereotactic ablative radiotherapy (SBRT) to a version that intentionally delivers higher radiation doses to the tumor (hotspots) in people with early-stage non-small cell lung cancer. The goal is to see if hotspots improve local tumor control without…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could chemo plus immunotherapy double the punch against tough lung cancers?
Disease control Not yet recruitingThis phase 3 trial investigates whether adding platinum-based chemotherapy to the immunotherapy drug tislelizumab helps people with a specific type of advanced lung cancer live longer without the disease worsening. Participants have non-small cell lung cancer that has spread, sho…
Phase: PHASE3 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study tests whether adding a new oral drug called fulvestaciclib to standard anti-HER2 and hormone therapy can help people with HR+/HER2+ advanced breast cancer live longer without their disease getting worse. Some participants receive the combo after initial chemotherapy, w…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Blood test could signal when to switch breast cancer therapy before tumors grow
Disease control Not yet recruitingThis phase 3 trial tests whether monitoring tumor DNA in the blood (ctDNA) can help doctors switch hormone therapy earlier in people with ER+/HER2- metastatic breast cancer. Participants whose ctDNA levels rise—before any symptoms or scans show progression—are randomly assigned t…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Smart T-Cell engager aims to outsmart tumors in first human test
Disease control Not yet recruitingThis early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…
Phase: PHASE1 • Sponsor: Kangabio AUSTRALIA LTD PTY • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental drug TJ037130 takes aim at advanced solid tumors
Disease control Not yet recruitingThis phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…
Phase: PHASE1 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Oral drug elraglusib aims to tame advanced solid tumors
Disease control Not yet recruitingThis study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…
Phase: PHASE1, PHASE2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug combo aims to tame aggressive lymphoma in frail patients
Disease control Not yet recruitingThis early-phase trial is testing a two-step treatment for elderly or unfit patients with untreated diffuse large B-cell lymphoma (DLBCL). First, patients receive the immunotherapy drug epcoritamab alone, then they receive epcoritamab combined with a reduced-dose chemotherapy coc…
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Double-Drug attack: new combo aims to tackle tough lung cancer
Disease control Not yet recruitingThis trial investigates whether combining two drugs—JS212 (given by IV) and JS111 (taken orally)—can safely and effectively shrink tumors in people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 20 participants who have not had prior treatment f…
Phase: NA • Sponsor: Huan Zhou • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo therapy aims to boost remission in Hard-to-Treat lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether a combination of the targeted drug glofitamab with chemotherapy (gemcitabine and oxaliplatin) can improve the effectiveness of a CAR-T cell therapy called lisocabtagene maraleucel in people with relapsed or refractory aggressive B-cell lymphomas. …
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant lung cancer
Disease control Not yet recruitingThis phase 2 trial tests whether adding an experimental drug called ABSK043 to the standard targeted therapy osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutated, PD-L1 positive). The study enrolls adults whose cancer has spread or cannot be surg…
Phase: PHASE2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Smart cancer therapy: tailoring lung cancer treatment with a simple blood test
Disease control Not yet recruitingThis trial investigates a personalized approach for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior treatment. Participants first take the targeted pill befotertinib for three weeks, then a blood test checks for minimal residual disease (MRD). T…
Phase: PHASE2 • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo aims to outperform standard care in aggressive lung cancer
Disease control Not yet recruitingThis Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…
Phase: PHASE3 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New care model aims to close cancer treatment gaps for people with mental illness
Disease control Not yet recruitingThis trial tests a 24-week virtual care program called BRIDGE NET for people with serious mental illness who are starting cancer treatment. The program brings together oncology and mental health teams to plan care, provide early psychiatric support, and regularly check in with pa…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Sitting up for cancer treatment: a new way to deliver proton therapy
Disease control Not yet recruitingThis study explores whether cancer patients can safely receive proton radiation therapy while sitting upright instead of lying down. The upright system is already FDA-cleared, and the goal is to see if it works reliably for a range of patients. Researchers will track treatment su…
Sponsor: Stanford University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Which CDK4/6 drug is easiest to tolerate in early breast cancer?
Disease control Not yet recruitingThis trial compares how well patients tolerate dalpiciclib versus abemaciclib or ribociclib when each is combined with standard hormone therapy for high-risk HR+/HER2- early breast cancer. About 456 patients who have completed initial local treatment will be randomly assigned to …
Phase: NA • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a targeted drug re-sensitize resistant breast cancer?
Disease control Not yet recruitingThis pilot trial tests whether adding the drug alisertib to usual care can help people with advanced HR+/HER2+ breast cancer whose disease has become resistant to standard treatments. Researchers want to see if alisertib can block communication between hormone receptors and HER2,…
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…
Phase: PHASE1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug duo aims to outsmart EGFR-mutant lung cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding an experimental drug called izalontamab brengitecan to the standard targeted therapy osimertinib works better than osimertinib alone or with chemotherapy for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Lung cancer combo therapy aims to clear tumors before surgery
Disease control Not yet recruitingThis phase II trial investigates whether combining the immunotherapy adebelizumab with other anti-tumor drugs, given before and after surgery, can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls adults aged 18-70 with stage II or IIIA dis…
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Double-Barreled drug attack targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThis trial is studying a combination of two targeted drugs, patritumab deruxtecan and trastuzumab deruxtecan, for people with a specific type of advanced breast cancer that is hormone receptor positive and has low or ultra-low levels of a protein called HER2. The study aims to fi…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with specific gene deletion
Disease control Not yet recruitingThis study tests an experimental drug called HSK41959, taken as a tablet, in combination with standard cancer treatments for people with advanced solid tumors that lack a gene called MTAP. The trial includes patients with non-small cell lung cancer, pancreatic cancer, and other a…
Phase: PHASE1 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a modified protein help immunotherapy fight a tough breast cancer?
Disease control Not yet recruitingThis study investigates whether adding isunakinra, a modified protein that blocks inflammation, can make triple-negative breast cancer more sensitive to standard immunotherapy and chemotherapy. The trial enrolls adults with newly diagnosed, locally advanced triple-negative breast…
Phase: PHASE1, PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug targets two cancer proteins in advanced tumors
Disease control Not yet recruitingThis trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…
Phase: PHASE1, PHASE2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug cocktail aims to shrink tough lung cancers
Disease control Not yet recruitingThis phase 2 trial tests whether combining the immunotherapy drug toripalimab with a specific chemotherapy regimen can shrink tumors in people with advanced small cell lung cancer that has progressed after prior treatments. Participants receive toripalimab plus a rotating schedul…
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Less may be more: smaller lung surgery tested against standard for early cancer
Disease control Not yet recruitingThis phase 3 trial compares two surgical approaches for early-stage non-small cell lung cancer with small (≤2 cm), solid-dominant tumors located deep within the lung. One group receives segmentectomy, which removes only the affected segment of the lung, while the other receives l…
Phase: NA • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could adding chemo to tarlatamab overcome resistance in lung cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether giving platinum-based chemotherapy (carboplatin and etoposide) together with the immunotherapy tarlatamab can help patients with advanced small-cell lung cancer whose disease has worsened while on tarlatamab alone. The study enrolls about 54 …
Phase: PHASE2 • Sponsor: University of Cologne • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug XYA02 takes on tough cancers in first human trial
Disease control Not yet recruitingThis study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…
Phase: PHASE1, PHASE2 • Sponsor: XYone Therapeutics, Inc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Protein zapper: new drug targets breast cancer from the inside
Disease control Not yet recruitingThis trial investigates TQB3126, a drug designed to destroy specific proteins that help breast cancer grow. It involves adults with breast cancer whose disease has worsened after prior treatments. The study will first find the safest dose and then test how well it works, alone or…
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…
Phase: PHASE1, PHASE2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
AR goggles could help surgeons spot cancer cells left behind during breast cancer surgery
Disease control Not yet recruitingThis trial tests whether special augmented-reality goggles can help surgeons find lymph nodes that may be missed during breast cancer surgery. The goggles show a fluorescent dye that collects in lymph nodes, allowing the surgeon to re-examine the area after the planned removal is…
Phase: NA • Sponsor: Ss. Cyril and Methodius University of Skopje • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Triple-Drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a combination of three drugs—tislelizumab, bevacizumab, and capecitabine—in people with advanced solid tumors. The trial focuses on two challenging groups: those whose cancers have stopped responding to immunotherapy and those with tumors that have spread to the …
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New PARP1 inhibitor targets Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …
Phase: PHASE1 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New Dual-Targeting drug VBC106 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…
Phase: PHASE1, PHASE2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New pill targets cancer growth at the genetic level
Disease control Not yet recruitingThis trial tests an experimental drug called SYH2095, taken as a daily pill, in people with advanced solid tumors that have no effective standard treatment. The drug blocks a protein (KAT6A/B) involved in cancer cell growth. The study aims to find a safe dose and check for early …
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo aims to outsmart lung cancer that resists immunotherapy
Disease control Not yet recruitingThis trial tests a combination of two drugs—tislelizumab and SYS6010—in people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after immunotherapy. Tislelizumab is an approved immunotherapy, and SYS6010 is an experimental drug that targets EGFR on can…
Phase: PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a statin make breast cancer therapy more effective?
Disease control Not yet recruitingThis study tests whether adding lovastatin, a common cholesterol-lowering drug, can help the cancer treatment trastuzumab deruxtecan work better in people with HER2-low or ultralow advanced breast cancer. About 60 participants will receive both drugs to see if more tumors shrink …
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Three-Drug cocktail aims to shrink breast tumors before surgery
Disease control Not yet recruitingThis study tests whether a combination of three drugs—kumorixilib, capecitabine, and letrozole—given before surgery can slow or shrink tumors in people with HR-positive, HER2-negative breast cancer. Participants take the drugs for six 28-day cycles, then have surgery. The main go…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug XTX501 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug called XTX501 in people with metastatic non-small cell lung cancer (NSCLC) or other advanced solid tumors. The goal is to see if the drug is safe and can shrink tumors. Participants receive XTX501 alone, and researchers monitor side effects and how wel…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a pill after surgery keep early lung cancer from coming back?
Disease control Not yet recruitingThis study looks at how well third-generation EGFR-targeted drugs work as follow-up treatment after surgery for people with early-stage non-small cell lung cancer that has certain high-risk features. Researchers will observe about 500 patients in China who have EGFR mutations and…
Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a diabetes drug slow breast cancer growth?
Disease control Not yet recruitingThis phase 2 trial investigates whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with early-stage hormone-receptor-positive breast cancer. Participants receive tirzepatide alone, the standard hormone therapy letrozole alone, or both t…
Phase: PHASE2 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could removing the primary tumor boost survival in stage IV breast cancer with Bone-Only spread?
Disease control Not yet recruitingThis trial investigates whether surgically removing the primary breast tumor, followed by standard systemic therapy, improves survival compared to systemic therapy alone in women with stage IV breast cancer that has spread only to a single bone site. The study enrolls women aged …
Phase: NA • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Custom-Made vaccine aims to stop lung cancer recurrence
Disease control Not yet recruitingThis study tests a personalized cancer vaccine, made specifically for each patient, to see if it is safe and can help prevent non-small cell lung cancer from coming back after surgery. The vaccine is given alone or together with an immunotherapy drug called toripalimab. The trial…
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New PET scan could predict who benefits from targeted lung cancer therapy
Disease control Not yet recruitingThis study investigates a drug called sacituzumab govitecan, which targets the TROP2 protein, in people with advanced non-small cell lung cancer that has stopped responding to standard EGFR-targeted treatments. Researchers are also comparing two types of PET/CT scans—one standard…
Phase: PHASE2 • Sponsor: Zhou Chengzhi • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could everyday heart drugs shield cancer patients from Radiation's cardiac toll?
Disease control Not yet recruitingThis study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation wil…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered herpes virus takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…
Phase: PHASE1, PHASE2 • Sponsor: Virogin Biotech Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a pill replace an IV for advanced breast cancer treatment?
Disease control Not yet recruitingThis Phase 3 trial compares two forms of the chemotherapy drug utidelone—a capsule taken by mouth versus an injection—both combined with another chemo drug, capecitabine, in people with HER-2 negative advanced breast cancer. The study aims to see if the oral capsule works as well…
Phase: PHASE3 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs, olomorasib and pembrolizumab, as a first treatment for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and a PD-L1 score between 1% and 49%. The main goal is to see how long patients live without t…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Bicycle therapies offer continued hope for advanced tumors
Disease control Not yet recruitingThis trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug aims to outperform current therapy in Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study compares a new experimental drug, BL-M07D1, to an approved therapy (DS-8201) in people with a common form of advanced breast cancer (HR-positive, HER2-low). The goal is to see if the new drug can delay cancer growth or improve survival. About 120 women aged 18 to 75 wi…
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a Cholesterol-Lowering injection help lung cancer patients stay on a key treatment?
Disease control Not yet recruitingThis study tests whether recakimab, an injectable drug that lowers cholesterol, can safely reduce high cholesterol caused by the lung cancer medication lorlatinib. The trial enrolls about 29 adults with advanced ALK-positive non-small cell lung cancer who developed high cholester…
Phase: PHASE4 • Sponsor: Hunan Cancer Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to stop triple negative breast cancer from returning
Disease control Not yet recruitingThis Phase 3 trial tests whether a combination of two drugs, trastuzumab rezetecan and adebrelimab, can prevent breast cancer from returning in people with triple negative breast cancer who still have cancer cells after initial chemotherapy and surgery. The study compares this ne…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could an asthma drug help fight lung cancer? early trial investigates
Disease control Not yet recruitingThis pilot study tests whether an inhaled drug called cromolyn sodium, already used for asthma, is safe and feasible for people with locally advanced lung cancer. The drug works by calming mast cells, which may play a role in tumor growth and treatment resistance. About 5 to 10 p…
Phase: PHASE1 • Sponsor: Carcinex Inc • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Herbal mix and cancer drug join forces to fight fluid in lungs
Disease control Not yet recruitingThis study tests whether adding a Chinese herbal formula (Xuanyin Ning) to a standard cancer drug (bevacizumab) can better control malignant pleural effusion—fluid buildup in the chest caused by advanced lung cancer. About 308 participants will receive either the herbal formula o…
Phase: NA • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Digital exercise program aims to boost recovery for breast cancer survivors
Disease control Not yet recruitingThis trial tests a 12-week program called EmpowerHer that combines home-based exercise via a mobile app with weekly in-person group sessions. It aims to improve health-related quality of life, reduce fatigue, anxiety, and depression, and increase physical fitness in breast cancer…
Phase: NA • Sponsor: University of Valencia • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Freezing breast tumors: a new hope for metastatic cancer control?
Disease control Not yet recruitingThis study investigates cryoablation, a procedure that freezes and destroys tumor tissue, for treating the primary breast tumor in women with metastatic breast cancer. The goal is to see if this minimally invasive approach can control the local tumor for 12 months while patients …
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Radiation may tame Treatment-Resistant breast cancer
Disease control Not yet recruitingThis study tests whether high-dose radiation can control tumors in people with locally advanced or recurrent metastatic breast cancer that has not responded to systemic therapy. Participants receive radical-dose radiotherapy, and those with large tumors (5 cm or more) may get a s…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New study aims to tame cholesterol side effect of lung cancer drug
Disease control Not yet recruitingThis study looks at the best way to manage high cholesterol caused by the targeted therapy lorlatinib in people with advanced ALK-positive non-small cell lung cancer. Some participants receive standard cholesterol-lowering drugs, while others get a more intensive combination. The…
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Personalized T-Cell therapy takes on advanced lung cancer
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called GK01 for people with advanced lung cancer who have not responded to standard treatments. The therapy uses a patient's own immune cells (T cells) that are specially prepared to attack the cancer. The main goal is to check safe…
Phase: EARLY_PHASE1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a radiofrequency device help fight advanced breast cancer?
Disease control Not yet recruitingThis pilot study tests whether adding a device called TheraBionic P1 to standard treatment can help women with metastatic triple negative breast cancer who have already tried two prior treatments. The device delivers low-level radiofrequency electromagnetic fields and is used alo…
Phase: NA • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New lung cancer cocktail aims to outperform current standard therapy
Disease control Not yet recruitingThis clinical trial compares a new three-drug combination (SYHX2011, carboplatin, and enlonstobart) against the standard three-drug regimen (nab-paclitaxel, carboplatin, and tislelizumab) as a first treatment for people with advanced squamous non-small cell lung cancer. The study…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New radiation approach aims to boost lung cancer treatment in poor responders
Disease control Not yet recruitingThis phase II trial tests a special type of radiation called lattice radiation therapy (LRT) combined with standard chemoimmunotherapy for people with stage III lung cancer that did not shrink enough after initial treatment. The LRT delivers high-dose radiation to specific spots …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo takes on advanced cancers
Disease control Not yet recruitingThis early-phase trial is testing whether two experimental drugs, SCTB41 and SCTB39G, given together every three weeks, are safe and can shrink tumors in adults with advanced solid tumors that have not responded to standard treatments. The study will enroll 112 participants acros…
Phase: PHASE1, PHASE2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug cocktail aims to outsmart resistant lung cancer
Disease control Not yet recruitingThis phase 4 trial tests whether combining two oral drugs—ensartinib and anlotinib—can shrink tumors or slow disease in people with ALK-positive non-small cell lung cancer that has become resistant to lorlatinib. About 80 adults with advanced (stage IIIB-IV) cancer will receive t…
Phase: PHASE4 • Sponsor: Qiming Wang • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to stop lung cancer recurrence in High-Risk patients
Disease control Not yet recruitingThis Phase 3 trial tests whether adding the experimental drug SYS6010 to standard immunotherapy can better prevent lung cancer from returning after surgery. About 570 adults with stage II-IIIB non-small cell lung cancer who did not respond well to pre-surgery treatment will be ra…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Targeted Antibody-Drug combo shows promise for Hard-to-Treat lung cancer
Disease control Not yet recruitingThis phase 2 trial tests the drug trastuzumab deruxtecan (T-DXd) in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has high levels of the HER2 protein. Participants receive T-DXd by IV every three weeks. The study measures how long the cancer stays und…
Phase: PHASE2 • Sponsor: Hunan Province Tumor Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for Hard-to-Treat breast cancer: drug combo trial launches
Disease control Not yet recruitingThis phase 3 trial is testing a drug called trastuzumab rezetecan, alone or combined with bevacizumab, in 140 women with advanced triple-negative breast cancer that has a specific immune-suppressed pattern. The goal is to see if the combination can delay cancer growth better than…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Extended look at gotistobart: could Long-Term use improve survival in advanced cancers?
Disease control Not yet recruitingThis extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …
Phase: PHASE3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New bispecific antibody D3L-002 enters first human trial for Hard-to-Treat cancers
Disease control Not yet recruitingThis Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…
Phase: PHASE1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Blood test could guide lung cancer treatment in new trial
Disease control Not yet recruitingThis Phase 2 trial is testing a drug called firmonertinib for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study uses a blood test (ctDNA) to decide if treatment should be adjusted over time. About 154 participants will receiv…
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cancer drug LNF2105 enters first human trials
Disease control Not yet recruitingThis early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…
Phase: PHASE1 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Inhaled mRNA therapy takes on solid tumors in first human trial
Disease control Not yet recruitingThis early-phase study tests an inhaled mRNA immunotherapy for adults with advanced lung cancer or solid tumors that have spread to the lungs. The treatment is given as a dry powder through an inhaler. The main goal is to check safety and find the best dose, with 60 participants …
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental injection trains immune cells inside the body to fight cancer
Disease control Not yet recruitingThis early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
First-in-Class cancer drug targets Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…
Phase: PHASE1, PHASE2 • Sponsor: VM Discovery, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Precision radiotherapy targets rare breast tumors by genetic fingerprint
Disease control Not yet recruitingThis trial investigates whether giving radiotherapy after surgery can prevent local recurrence in people with a rare breast tumor called phyllodes tumor, specifically those with high-risk molecular subtypes (MN1 or MN2). Participants who have had complete tumor removal will be ra…
Phase: NA • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a single day of radiation replace weeks of treatment for breast cancer?
Disease control Not yet recruitingThe SASHA trial is testing whether a single, high-dose radiation treatment delivered directly to the tumor site over one day is safe and effective for women with early-stage breast cancer. The study will enroll 134 women aged 40-85 who have already had a lumpectomy. Researchers w…
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radiation approach aims to cut treatment time for early breast cancer
Disease control Not yet recruitingThis study tests a risk-based approach to radiation after breast-conserving surgery for early breast cancer. Depending on individual risk, patients receive either whole-breast or partial-breast radiation in fewer, larger doses (hypofractionation). The goal is to maintain cancer c…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough lung cancer: combo therapy enters phase II trial
Disease control Not yet recruitingThis study tests a new drug (BL-M14D1) combined with an approved immunotherapy (atezolizumab) in 36 adults with extensive-stage small cell lung cancer that has no standard treatment. The goal is to see if the combination can shrink tumors and control the disease. Participants mus…
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Tiny drug particles aim to shrink breast tumors
Disease control Not yet recruitingThis Phase 2 trial tests BL0175, a nano-medicine that delivers cancer-fighting drugs directly into tumors. It enrolls 120 postmenopausal women with HR+/HER2- advanced breast cancer. Researchers compare different doses to find the safest and most effective one for shrinking tumors…
Phase: PHASE2 • Sponsor: Shanghai Best-Link Bioscience, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis early-phase study tests an oral drug called SNH-118110 in 240 adults with advanced solid tumors that have a specific genetic change (RET). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have tried other treatm…
Phase: PHASE1 • Sponsor: ScinnoHub Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to keep platelets up during breast cancer chemo
Disease control Not yet recruitingThis phase 2 study tests whether the drug hetrombopag can prevent dangerously low platelet counts caused by chemotherapy in breast cancer patients at high risk. About 126 participants will be split into three groups: one getting no preventive drug, one taking hetrombopag continuo…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets tough cancers with KRas G12V mutation
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…
Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a Macrophage-Targeting drug supercharge CAR-T therapy?
Disease control Not yet recruitingThis trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer mor…
Phase: PHASE1 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Promising new drug combo takes on advanced lung cancer in major trial
Disease control Not yet recruitingThis study tests a new drug combination (SYS6010 plus enlonstobart) against the usual immunotherapy with chemotherapy for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). About 500 adults aged 18-75 who have not had prior treatment for their…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a simpler surgery spare breast cancer patients from unnecessary side effects?
Disease control Not yet recruitingThis study looks at whether people with advanced breast cancer that has spread to lymph nodes can safely have a less extensive armpit surgery after chemotherapy. Instead of removing many lymph nodes, doctors will remove only a few and then give radiation. The goal is to see if th…
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Fat grafting vs. flap surgery: which is better for breast reconstruction after radiation?
Disease control Not yet recruitingThis study compares two methods of breast reconstruction in women who had a mastectomy and radiation for breast cancer: autologous fat transfer (AFT) and DIEP flap surgery. About 280 participants will be randomly assigned to one of the two procedures. The main goal is to see if A…
Phase: NA • Sponsor: Maastricht University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New Antibody-Drug conjugate enters early human trials for advanced cancers
Disease control Not yet recruitingThis Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
Phase: PHASE1 • Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail aims to boost lung cancer treatment before radiation
Disease control Not yet recruitingThis Phase 2 trial tests whether adding two drugs (benmelstobart and anlotinib) to standard chemotherapy before chemoradiation helps people with stage III lung cancer that cannot be removed by surgery. 152 participants will be randomly assigned to receive either the new induction…
Phase: PHASE2 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New chemo combo shows promise for tough lung cancer
Disease control Not yet recruitingThis Phase 2 trial tests whether adding lurbinectedin to paclitaxel works better than paclitaxel alone for people with advanced small cell lung cancer that has returned after first treatment. About 69 adults will be randomly assigned to one of two groups. The study measures how m…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo aims to keep lung cancer at bay
Disease control Not yet recruitingThis study tests whether adding a new drug (BL-B01D1) to the standard pill osimertinib can help people with a certain type of Stage III lung cancer stay cancer-free longer. Participants must have an EGFR gene mutation and have already completed chemotherapy and radiation without …
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo shows promise for tough lung cancer
Disease control Not yet recruitingThis study tests a combination of two drugs, QL1706 and anlotinib, for people with advanced small cell lung cancer who have already tried at least two prior treatments. The goal is to see if the combination helps control the cancer and extends survival. About 120 adults aged 18 t…
Phase: PHASE2, PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail aims at resistant lung cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining two drugs, lomustine and anlotinib, can shrink tumors or slow disease in people with extensive-stage small cell lung cancer that has not responded to at least two prior treatments. About 46 participants will receive the drug combination …
Phase: PHASE2 • Sponsor: Yayi He • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New injection YKYY031 enters human testing for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …
Phase: PHASE1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Smart breathing device aims to speed lung recovery after cancer surgery
Disease control Not yet recruitingThis trial tests whether an intelligent breathing exercise device helps people recover lung function after surgery for non-small cell lung cancer. Participants use the device for breathing exercises twice daily for 30 days after surgery, while a comparison group receives standard…
Phase: NA • Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Inhaled therapy aims to cut lung Tumors' sugar supply
Disease control Not yet recruitingThis pilot study tests whether an inhaled drug called AER101 can reduce glycolysis—the process cancer cells use to break down sugar for energy—in early-stage non-small cell lung cancer. Participants inhale the drug three times daily for two weeks before their scheduled surgery. T…
Phase: EARLY_PHASE1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…
Phase: PHASE2 • Sponsor: GV20 Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug targets hard-to-treat cancers in early trial
Disease control Not yet recruitingThis study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…
Phase: PHASE2 • Sponsor: Haihua Yuan • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo aims to keep lung cancer at bay longer
Disease control Not yet recruitingThis study tests whether adding tarlatamab to durvalumab after standard chemotherapy and radiation can delay cancer return and extend life in people with limited-stage small cell lung cancer. Tarlatamab works by helping immune cells recognize and attack cancer cells. About 430 pa…
Phase: PHASE3 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising drug cocktail targets Hard-to-Treat lung cancer
Disease control Not yet recruitingThis Phase II trial tests a combination of two drugs, trastuzumab rezetecan and ivonescimab, in 30 people with advanced non-small cell lung cancer that has HER2 gene abnormalities. The goal is to see if the combo can control the cancer and delay progression. Participants must hav…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug challenger takes on leading therapy for advanced breast cancer
Disease control Not yet recruitingThis study tests whether a new drug, trastuzumab rezetecan, works as well as or better than the current drug trastuzumab deruxtecan for women with advanced HER2-positive breast cancer that has worsened after previous treatment. About 100 women will be randomly assigned to one of …
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New study aims to keep breast cancer patients on track with lifesaving pills
Disease control Not yet recruitingThis study looks at whether a structured support program can help people with early-stage, hormone-positive breast cancer stick to their ribociclib medication (taken with an aromatase inhibitor). About 90 participants will be split into two groups: one gets standard care, the oth…
Phase: PHASE4 • Sponsor: Institute of Oncology Ljubljana • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug duo aims to stop aggressive breast cancer's return
Disease control Not yet recruitingThis study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), followed by standard chemotherapy (capecitabine), works better than capecitabine alone to keep early-stage, high-risk triple-negative breast cancer from returning. About 420 women without BRCA gene mutations …
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for lung cancer patients: drug combo targets tough tumors
Disease control Not yet recruitingThis study tests a new combination of two drugs (becotatug vedotin and pucotenlimab), with or without radiation, as a first treatment for people with advanced non-small cell lung cancer that has a specific protein (EGFR) on its surface. About 39 participants will receive the drug…
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New antibody drug aims to outsmart tumors by targeting two immune pathways
Disease control Not yet recruitingThis study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …
Phase: PHASE1, PHASE2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Lung cancer surgery showdown: less invasive sampling may match full dissection
Disease control Not yet recruitingThis study tests whether taking only a few lymph node samples (selective sampling) works as well as removing all nearby lymph nodes (systematic dissection) in people with stage IIA-IIIB non-small cell lung cancer. All participants will first receive chemotherapy combined with imm…
Phase: PHASE3 • Sponsor: Wen-zhao ZHONG • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…
Phase: PHASE1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New targeted pill could boost lung cancer surgery success
Disease control Not yet recruitingThis phase II trial is testing whether the targeted therapy firmonertinib, taken as a pill for 8 to 16 weeks before surgery, can shrink tumors in people with stage II-IIIB EGFR-mutated lung adenocarcinoma. About 60 participants will receive the drug and then undergo surgery to re…
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to keep lymphoma in check after CAR-T treatment
Disease control Not yet recruitingThis study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New lung cancer cocktail trial aims to shrink tumors
Disease control Not yet recruitingThis phase 2 trial tests a new drug called SKB571 combined with other cancer medicines in 150 people with non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. Participants will receive the drugs by injection or mouth, and re…
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for hard-to-treat breast cancer: drug duo targets hidden mutations
Disease control Not yet recruitingThis study tests a combination of two drugs, zongertinib and fulvestrant, in people with advanced breast cancer that is hormone receptor-positive and HER2-negative but has a specific HER2 gene mutation. The goal is to see if the combination shrinks tumors. About 25 adults will ta…
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug Hemay5087 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…
Phase: PHASE1 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug HH160 enters first human tests for advanced tumors
Disease control Not yet recruitingThis early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Glow-in-the-Dark cancer detector aims to cut repeat breast surgeries
Disease control Not yet recruitingThis study will test a device called LumiSystem that helps surgeons see if any cancer cells are left behind during breast cancer surgery. About 1500 women having a lumpectomy will be included. The goal is to see if using this imaging tool reduces the number of patients who need a…
Sponsor: Lumicell, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New vaccine combo takes on tough lung cancer in early trial
Disease control Not yet recruitingThis early-phase study tests a new cancer vaccine (EVM14) combined with an immunotherapy drug (ivonescimab) in 13 people with advanced squamous non-small cell lung cancer that has not been treated before. The main goals are to check safety and find the right dose, while also look…
Phase: PHASE1 • Sponsor: Everest Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Triple threat: radiation plus Immuno-Chemo shows promise for lung cancer
Disease control Not yet recruitingThis study tests whether adding a special type of radiation (SF-SBRT) to the usual combination of immunotherapy (toripalimab) and chemotherapy helps people with stage II-III non-small cell lung cancer live longer without the cancer coming back. About 200 participants will be rand…
Phase: PHASE3 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug CS231295 enters first human trial for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …
Phase: PHASE1 • Sponsor: ThalassaX Therapeutics United States Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Can a simple CT scan catch lung cancer earlier in kuwait?
Diagnosis Not yet recruitingThis pilot study will offer low-dose CT scans to about 500 high-risk smokers aged 50-80 in Kuwait to see if this screening approach is practical and acceptable. The goal is to measure how many people agree to screening, identify barriers, and evaluate the use of AI to help read t…
Phase: NA • Sponsor: Sulaiman Khadadah • Aim: Diagnosis
Last updated Aug 18, 2026 02:00 UTC
-
New radioactive antibody could light up Hard-to-Treat cancers
Diagnosis Not yet recruitingThis early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…
Phase: PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Which lung biopsy method is safer and more accurate?
Diagnosis Not yet recruitingThis trial compares two established biopsy methods for small lung nodules (≤2 cm): CT-guided percutaneous biopsy and shape-sensing robotic-assisted bronchoscopy with cone-beam CT. The goal is to see which approach is more effective at diagnosing cancer and which has fewer complic…
Phase: PHASE4 • Sponsor: Intuitive Surgical • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
AI could spot hidden cancers on routine CT scans
Diagnosis Not yet recruitingThis study will test an artificial intelligence system that screens for breast, liver, kidney, and bladder cancers using standard CT scans taken for other reasons. Researchers plan to enroll 100,000 participants to see if the AI can catch tumors earlier and help doctors reduce mi…
Sponsor: Lian Yang • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
A simple breath test might spot multiple cancers before symptoms appear
Diagnosis Not yet recruitingThis trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Can a new imaging tracer outperform standard scans in finding hidden tumors?
Diagnosis Not yet recruitingThis trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…
Phase: NA • Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
No-Squeeze 3D breast scan could transform cancer detection
Diagnosis Not yet recruitingThis study tests a new type of breast imaging called upright breast CT (UBCT) that creates a 3D picture without compressing the breast like a mammogram. It uses a low radiation dose similar to standard mammography. The goal is to see if this device can help doctors detect breast …
Phase: NA • Sponsor: University of Arizona • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
New imaging agent aims to sharpen cancer detection
Diagnosis Not yet recruitingThis early-phase study tests a new radioactive imaging probe that targets a protein called FAP, found on many solid tumors. The probe is used with PET or SPECT scans to see if it can better locate tumors and determine if they have spread, compared to standard FDG-PET imaging. The…
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers
Diagnosis Not yet recruitingThis early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…
Phase: EARLY_PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New PET tracer could sharpen cancer detection
Diagnosis Not yet recruitingThis early-phase study tests a new radioactive tracer called [68Ga]Ga-FFD for PET imaging in healthy volunteers and people with solid tumors. The goal is to see if it is safe, where it goes in the body, and how well it spots tumors compared to standard imaging. Researchers will a…
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers and fibrosis in one scan
Diagnosis Not yet recruitingThis study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …
Phase: PHASE1, PHASE2 • Sponsor: Martin Huellner • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Could ultrasound screening catch breast cancer earlier in older women?
Diagnosis Not yet recruitingThis study investigates whether offering regular breast ultrasound screening to women aged 65 to 80 can increase the rate of early-stage breast cancer detection compared to routine health check-ups. Over 82,000 women from communities in China will be assigned to either receive st…
Phase: NA • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
Breath of discovery: simple test may sniff out lung cancer
Diagnosis Not yet recruitingThis pilot study explores whether a breath sample collected with the VosCryo device can provide enough cellular material to help diagnose advanced lung cancer. Researchers will compare breath samples from 12 people with late-stage lung cancer and 12 healthy relatives to see if th…
Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
Spinal fluid DNA test could personalize brain cancer therapy
Diagnosis Not yet recruitingThis study explores whether analyzing tumor DNA in cerebrospinal fluid can help doctors make better treatment decisions for people with malignant brain tumors or brain metastases from lung or breast cancer. Participants undergo a standard spinal tap or fluid collection, and the f…
Phase: NA • Sponsor: Alireza Mansouri • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
AR goggles could help surgeons spot cancer in lymph nodes in real time
Diagnosis Not yet recruitingThis study tests whether augmented-reality goggles, combined with a special dye called indocyanine green (ICG), can accurately identify cancerous lymph nodes during breast cancer surgery. Two hundred adults with breast cancer will take part. The goggles use near-infrared light to…
Sponsor: Ss. Cyril and Methodius University of Skopje • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
AI model aims to predict breast cancer therapy success
Diagnosis Not yet recruitingThis study will develop and test an AI model that combines MRI, ultrasound, digital pathology, and patient data to predict how well breast cancer responds to neoadjuvant therapy. Researchers will analyze data from 1,800 participants across multiple centers. The goal is to help do…
Phase: NA • Sponsor: Yunnan Cancer Hospital • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New imaging agent aims to light up hidden tumors
Diagnosis Not yet recruitingThis early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …
Phase: PHASE1 • Sponsor: Robert Flavell, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
AI could help doctors diagnose lung cancer faster during a bronchoscopy
Diagnosis Not yet recruitingThis study tests an artificial intelligence (AI) prototype designed to quickly evaluate tissue samples taken during a bronchoscopy, a procedure used to diagnose lung cancer. The AI analyzes microscope images of the samples to determine if they are adequate for diagnosis and wheth…
Sponsor: Azienda Ospedaliera di Rilievo Nazionale A.Cardarelli • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
New imaging agent could sharpen lung cancer detection
Diagnosis Not yet recruitingThis early-phase trial will test a new radioactive tracer called [68Ga]Ga-PentixaFor in 15 people with metastatic small cell lung cancer. The goal is to see if this PET-CT scan can find tumors as well as the standard FDG PET-CT scan, both at diagnosis and when the disease gets wo…
Phase: EARLY_PHASE1 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New radioactive tracers could spot cancers more clearly
Diagnosis Not yet recruitingThis early-phase study will test two radioactive tracers designed to light up certain solid tumors on scans. Twenty adults with breast, head and neck, pancreatic cancer, or glioma will receive an injection of the tracers and then undergo PET/CT and SPECT/CT imaging. The goal is t…
Phase: EARLY_PHASE1 • Sponsor: Hua Pang • Aim: Diagnosis
Last updated Jun 27, 2026 13:08 UTC
-
New biopsy method may spare breast cancer patients from unnecessary surgery
Diagnosis Not yet recruitingThis study tests whether a vacuum-assisted biopsy can accurately tell if breast cancer has been completely eliminated by chemotherapy, compared to the standard surgical removal. About 100 women with breast cancer who have finished chemotherapy will receive the biopsy, and results…
Phase: NA • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New Dual-Targeted PET scan aims to spot cancers more clearly
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…
Phase: NA • Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New ultrasound technique may predict chemo success after just one dose
Diagnosis Not yet recruitingThis study tests whether a special ultrasound technique (super-resolution imaging) can predict if breast cancer will completely respond to chemotherapy after just one cycle. Researchers will enroll 150 women with invasive breast cancer scheduled for chemotherapy. The goal is to s…
Sponsor: Anhui Provincial Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
Can a new drug shield nerves from Chemotherapy's side effects?
Prevention Not yet recruitingThis phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…
Phase: PHASE2 • Sponsor: Sironax USA, Inc. • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Psilocybin trial aims to shield cancer patients from chemo nerve pain
Prevention Not yet recruitingThis Phase 2 trial tests whether psilocybin, a psychedelic compound, can prevent or lessen chemotherapy-induced peripheral neuropathy (nerve damage) in people with breast, colorectal, or head and neck cancer. About 83 participants will receive either psilocybin, a low-dose placeb…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Ear acupressure: a new weapon against chemotherapy side effects?
Prevention Not yet recruitingThis trial tests whether adding auricular acupressure—using small seed patches on specific ear points—to standard antiemetic medication can better prevent nausea and vomiting in people receiving highly emetogenic chemotherapy. About 332 patients with solid tumors will be randomly…
Phase: NA • Sponsor: China Medical University, China • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Quitlines may double as lung cancer screening boosters
Prevention Not yet recruitingThis study compares two ways to share lung cancer screening information with people who call tobacco quitlines. Participants are quitline clients aged 50 to 80 with a heavy smoking history. One approach offers extra coaching and navigation support. The goal is to see which method…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jul 24, 2026 00:00 UTC
-
Personalized navigation may boost cancer screening in high-risk communities
Prevention Not yet recruitingThis study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …
Phase: NA • Sponsor: Hunan Cancer Hospital • Aim: Prevention
Last updated Jul 10, 2026 00:00 UTC
-
Exercise may shield cancer Patients' hearts from chemo damage
Prevention Not yet recruitingThis study will test whether a 12-week program of supervised aerobic and strength exercises can prevent heart problems in 60 adults undergoing chemotherapy for cancer. Participants will be split into an exercise group and a usual-care group. Researchers will measure heart functio…
Phase: NA • Sponsor: Federal University of Maranhao • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
Acupuncture needles aim to stop Chemo's nerve pain
Prevention Not yet recruitingThis study tests whether electroacupuncture (using mild electric pulses on needles) plus tiny thumbtack needles can prevent nerve damage caused by chemotherapy in people with early-stage cancer. About 278 patients with breast, stomach, bowel, lung, or ovarian cancer will receive …
Phase: NA • Sponsor: Affiliated Hospital of Qinghai University • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Acupuncture with a jolt: could needles shield nerves from chemo?
Prevention Not yet recruitingThis study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…
Phase: NA • Sponsor: Affiliated Hospital of Qinghai University • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Can everyday moisturizers soothe cancer Therapy's skin toll?
Symptom relief Not yet recruitingThis trial tests whether cosmeceutical moisturizers can ease skin dryness in people with cancer who experience skin side effects from treatments like chemotherapy or immunotherapy. Participants apply the moisturizers daily for 2-4 weeks and report changes in dryness severity. The…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Aug 18, 2026 02:00 UTC
-
New study tests simple home program to fight fatigue in breast cancer survivors
Symptom relief Not yet recruitingThis study looks at whether a 6-week home program combining exercise and a limited eating window is practical and helpful for breast cancer survivors who are on hormone therapy and feel fatigued. Twenty participants will follow a plan to increase their steps, do resistance band e…
Phase: NA • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Aug 18, 2026 02:00 UTC
-
Can acupuncture soothe the mind and body in breast cancer?
Symptom relief Not yet recruitingThis trial tests whether personalized acupuncture—chosen together by the patient and clinician—can ease psychosomatic symptoms like anxiety, depression, sleep problems, and fatigue in women with breast cancer. Participants are divided into groups based on their symptom patterns a…
Phase: NA • Sponsor: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Exercise during chemo: a new weapon to preserve strength?
Symptom relief Not yet recruitingThis trial tests whether a supervised exercise program is practical and safe for women with early-stage breast cancer receiving chemotherapy before surgery. Participants either join a supervised aerobic and strength training program twice a week during chemo, or receive usual car…
Phase: NA • Sponsor: King Hamad University Hospital, Bahrain • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
One injection or many? a test to ease breast surgery pain
Symptom relief Not yet recruitingThis trial asks whether a single nerve block can match the pain relief of multiple nerve blocks after breast cancer surgery. Women aged 18-65 scheduled for breast cancer surgery will receive either one or several injections of a local anesthetic near the spine. The study measures…
Phase: NA • Sponsor: Antalya City Hospital • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
A lifeline for cancer caregivers: can simple phone support reduce their stress?
Symptom relief Not yet recruitingThis pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Virtual therapy may ease breast cancer treatment side effects
Symptom relief Not yet recruitingThis study tests a 6-session telehealth program called STRIDE, which uses cognitive behavioral therapy to help women with hormone-positive breast cancer manage side effects from adjuvant endocrine therapy. Participants will be randomly assigned to either the STRIDE program or usu…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Free money for cancer patients: $1,000 monthly cash cards tested in new study
Symptom relief Not yet recruitingThis pilot study will give 20 early-stage cancer patients a preloaded cash card with $1,000 each month. The goal is to see if this simple cash support can prevent financial hardship, like debt or missed rent, and improve treatment outcomes. Researchers will measure how many peopl…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can a stronger radiation dose ease bulky tumors better?
Symptom relief Not yet recruitingThis study compares standard palliative radiotherapy (24 Gray in 3 sessions) with a higher dose (27 Gray in 3 sessions) for people with large metastatic tumors. The goal is to see if the higher dose improves tumor control without more side effects. About 20 adults with solid tumo…
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Could essential oils tame chemo nausea? a new trial puts aromatherapy to the test
Symptom relief Not yet recruitingThis phase III trial is testing whether adding aromatherapy—using lemon, lavender, and peppermint essential oils—to standard anti-nausea medication can better prevent nausea and vomiting in breast cancer patients receiving highly emetogenic chemotherapy. About 374 patients will b…
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can a virtual wellness program help women with advanced breast cancer?
Symptom relief Not yet recruitingThis study tests a virtual group lifestyle program for women with metastatic breast cancer. The goal is to see if more support helps them stick with healthy habits like diet and exercise. One hundred women will take part, and researchers will track safety and how well they follow…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Magic mushroom compound tested for cancer pain relief
Symptom relief Not yet recruitingThis phase II trial tests whether low-dose psilocybin, a compound from magic mushrooms, combined with psychotherapy is safe and effective for easing chronic pain in cancer patients who already take opioids. Twenty adults with active cancer and moderate to severe pain will receive…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Nature escapes in a headset: a new way to calm cancer infusions?
Symptom relief Not yet recruitingThis randomized trial tests whether immersive virtual reality (VR) can reduce anxiety in people with lung cancer during immunotherapy or chemo-immunotherapy infusions. Half of the 60 participants will use a VR headset showing calming nature scenes during four infusion visits, whi…
Phase: NA • Sponsor: Dott.Claudio Sini • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
A virtual Walk-Through of radiotherapy may calm cancer Patients' nerves
Symptom relief Not yet recruitingMany cancer patients feel anxious before radiotherapy, partly due to unfamiliar equipment and procedures. This trial tests whether adding a simulation-based education session — a virtual preview of the treatment environment — before standard education can reduce that anxiety and …
Phase: NA • Sponsor: University Medical Center Goettingen • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Chatbot coach for cancer care: new study tests digital sidekick for lung patients
Symptom relief Not yet recruitingThis study tests a LINE chatbot that gives visual, interactive tips to help lung cancer patients handle side effects from their targeted therapy. About 178 adults with advanced lung cancer will either get usual care or also access the chatbot. The goal is to see if the chatbot bo…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
A new program aims to help teens thrive when a parent faces cancer
Symptom relief Not yet recruitingThis study is testing a family-centered program called SHINE, designed to support teenagers aged 10 to 17 who have a parent diagnosed with cancer. The program includes about four sessions over eight weeks, focusing on cancer education, family communication, coping skills, and emo…
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New support program aims to help breast cancer patients stick with treatment
Symptom relief Not yet recruitingThis study tests a nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer who are taking a specific combination of drugs. The program provides education, symptom management tips, and coping strategies over about 12 weeks. Researchers want to see …
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Facing the fear: can talk therapy help couples live beyond cancer?
Symptom relief Not yet recruitingThis trial tests whether a type of talk therapy called Acceptance and Commitment Therapy (ACT) can help cancer survivors and their spouses cope with the fear that cancer might return. It compares ACT to a more traditional therapy, Cognitive Behavioural Therapy (CBT), in a two-arm…
Phase: NA • Sponsor: University Center of Tumor Diseases, Frankfurt University Hospital • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
AI therapy coach aims to ease distress in seriously ill seniors
Symptom relief Not yet recruitingThis study tests whether an AI-powered program can help older adults with serious illnesses like cancer or heart disease manage emotional distress. Participants receive short videos and daily check-ins from a chatbot that teaches practical coping skills, all from their own phone.…
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Exercise after chemo: could a simple walking program protect your heart?
Symptom relief Not yet recruitingThis study looks at whether an 8-week aerobic exercise program can improve blood vessel function in women who have finished chemotherapy for non-metastatic breast cancer. Forty women will exercise three times a week for 30 minutes at a moderate pace. Researchers will measure arte…
Phase: NA • Sponsor: Loyola University • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Could gentle yoga and breathing ease Cancer's lingering toll?
Symptom relief Not yet recruitingThis trial tests whether mind-body practices like breathwork, meditation, and gentle yoga can improve quality of life, stress, and sleep in people who have recently finished cancer treatment. Participants will practice these techniques weekly for six weeks while wearing an activi…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can a simple text message transform cancer care?
Symptom relief Not yet recruitingThis trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…
Phase: NA • Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can an AI chatbot ease fertility worries for young cancer survivors?
Symptom relief Not yet recruitingThis pilot trial tests whether a chatbot powered by large language models can help adolescent and young adult cancer survivors address reproductive concerns. Participants will be randomly assigned to use the chatbot or read an electronic brochure with similar information. The stu…
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
A single zoom class might ease cancer pain for american indians
Symptom relief Not yet recruitingThis trial tests whether a single, two-hour online class called Empowered Relief can help American Indian adults with cancer-related pain. Participants learn three pain relief skills, create a personal plan, and get access to a free audio app for daily practice. The study aims to…
Phase: NA • Sponsor: University of Oklahoma • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Teamwork in care: could shared Self-Care lessons ease the toll of breast cancer treatment?
Symptom relief Not yet recruitingThis trial tests whether a structured education program, given to both breast cancer patients and their primary caregivers together, can improve self-care behaviors and reduce anxiety for patients, while also easing caregiver anxiety and burden. The program involves four weekly s…
Phase: NA • Sponsor: Ulviye Aydan NACAK • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
A virtual pharmacy visit may ease opioid fears for cancer patients
Symptom relief Not yet recruitingThis pilot study tests whether a group telehealth session led by a palliative care pharmacist can help cancer patients better understand and manage their opioid pain medications. Many patients struggle with side effects, complex dosing, and fear of addiction, which can lead to un…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Which nerve block eases mastectomy pain best? a Head-to-Head trial
Symptom relief Not yet recruitingThis trial compares two ultrasound-guided nerve blocks for pain after modified radical mastectomy: the newer serratus posterior superior intercostal plane block (SPSIPB) and the established serratus anterior plane block (SAPB). Seventy women undergoing mastectomy will receive one…
Phase: NA • Sponsor: Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
AI reads your cancer care wishes — could it keep you out of the hospital?
Symptom relief Not yet recruitingThis trial tests whether sending AI-generated summaries of a patient's serious illness conversations to their care team at hospital admission can improve care. The summaries, created by a large language model, highlight the patient's goals and preferences. The study enrolls adult…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
A listening ear for cancer patients: can a care coordinator improve serious illness conversations?
Symptom relief Not yet recruitingThis trial tests whether a communication and care coordinator (CCC) can improve serious illness conversations and quality of life for adults with advanced or high-risk cancer. Participants in the intervention group will have six structured sessions over three months to discuss th…
Phase: NA • Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
A personalized approach to breathlessness: could a stepped-care program offer relief for lung cancer patients?
Symptom relief Not yet recruitingShortness of breath, or dyspnea, affects most lung cancer patients and often persists despite standard treatments. This pilot study tests a stepped-care behavioral intervention called INSPIRE, which starts with brief coping skills and adds more intensive psychological support onl…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Texting your symptoms: a digital coach for cancer side effects?
Symptom relief Not yet recruitingThis trial tests whether a digital platform that sends symptom check-ins and self-care tips via text message can help people with head and neck or lung cancer report their health more consistently. Participants either receive standard symptom questionnaires or get extra monitorin…
Phase: NA • Sponsor: Henry Ford Health System • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
New program aims to give veterans with advanced cancer a stronger voice in their End-of-Life care
Symptom relief Not yet recruitingThis study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Exercise as medicine: can a 12-week program reverse muscle loss in breast cancer survivors?
Symptom relief Not yet recruitingThis trial tests whether a 12-week structured exercise program, called "Exercise for Muscle Health," can improve muscle mass, strength, and physical function in breast cancer survivors who have sarcopenia—a condition of muscle loss and weakness. About 104 women who have finished …
Phase: NA • Sponsor: Capital Medical University • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
A smartphone program aims to ease the emotional toll of fertility loss in young cancer survivors
Symptom relief Not yet recruitingThis trial tests whether a guided digital program delivered through a mobile app can reduce anxiety and depression in young adults (ages 18–40) who have fertility-related distress after a cancer diagnosis. Participants use the app to complete four modules covering coping skills, …
Phase: NA • Sponsor: Gadjah Mada University • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Ice vs spray: which stops chemo mouth pain?
Symptom relief Not yet recruitingThis trial compares two simple treatments—sucking on ice chips or using a lidocaine spray—to see which better prevents or reduces painful mouth sores caused by chemotherapy. About 60 adults with cancer who are about to receive chemotherapy will be randomly assigned to one of the …
Phase: NA • Sponsor: Hanady Jabbar Mahmood • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Strumming through treatment: can ukulele lessons shield teen brains from Radiation's toll?
Symptom relief Not yet recruitingThis pilot trial tests whether a program of virtual ukulele lessons, called STRUM, can help teenagers preserve cognitive function and emotional resilience while undergoing radiation therapy for cancer. The study enrolls adolescents aged 12 to 17 who are receiving initial radiatio…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Digital sleep and mood programs put to the test for breast cancer survivors
Symptom relief Not yet recruitingThis trial tests whether self-guided digital programs can reduce both insomnia and depression in breast cancer survivors. Participants use an online insomnia program or a mental health program, either alone or in sequence, to see which approach works best. The goal is to find a s…
Phase: NA • Sponsor: University of Virginia • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Belly button patch may fight cancer fatigue without drugs
Symptom relief Not yet recruitingThis study tests whether a traditional Chinese medicine patch placed on the belly button (Shenque acupoint) can reduce fatigue in cancer patients about to start radiotherapy. Eighty adults with cancer-related fatigue will receive either the real herbal patch or a sham patch daily…
Phase: NA • Sponsor: China Medical University Hospital • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Snakehead fish and turmeric: a kitchen remedy put to the test against cancer-related malnutrition
Symptom relief Not yet recruitingThis trial investigates whether a daily supplement of Channa striata (snakehead fish) and curcuma (turmeric) can improve nutritional status, reduce inflammation, and enhance quality of life in women with breast cancer undergoing chemotherapy. Over one month, 76 participants will …
Phase: NA • Sponsor: DINA KEUMALA SARI • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Money worries and cancer: can talking about both ease the burden?
Symptom relief Not yet recruitingThis pilot study tests a financial psycho-oncology program for cancer patients facing financial hardship. Participants attend six one-hour sessions over three months that combine emotional support with practical financial education. The study aims to see if the program is feasibl…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
A scented soak for cancer symptoms: can lavender foot baths soothe pain and fatigue?
Symptom relief Not yet recruitingThis trial investigates whether daily aromatherapy foot baths with lavender essential oil can help cancer patients manage pain, sleep quality, and fatigue. Over five days, one group receives a 20-minute foot bath with lavender oil, while a control group receives routine care only…
Phase: NA • Sponsor: Ankara Yildirim Beyazıt University • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
Home workouts may ease Chemotherapy's toll on breast cancer patients
Symptom relief Not yet recruitingThis study tests whether a 24-week, remotely supervised exercise program combining aerobic intervals and resistance training can improve physical health and quality of life in women with breast cancer undergoing chemotherapy. Participants, aged 30-65 with stage II-III breast canc…
Phase: NA • Sponsor: Riga Stradins University • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
AI avatar could help cancer patients remember treatment details
Symptom relief Not yet recruitingThis trial tests an AI-powered avatar called ELISA that helps cancer patients learn about their treatment. Patients starting a new cancer therapy often struggle to remember complex information. The avatar provides personalized answers based on approved content. The study compares…
Phase: NA • Sponsor: Dr. Mark Mulder • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Could an AI writing coach help chemo patients feel less anxious?
Symptom relief Not yet recruitingThis study tests whether an AI-assisted expressive writing program can reduce anxiety, emotional distress, and improve quality of life in adults receiving chemotherapy for any type of cancer. Participants are randomly assigned to either use the AI writing tool alongside their usu…
Phase: NA • Sponsor: Alexandria University • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Could a Post-Workout protein shake help breast cancer survivors rebuild muscle?
Symptom relief Not yet recruitingThis study tests whether taking a high dose of whey protein after each workout helps breast cancer survivors gain more muscle and lose more fat compared to exercise alone. Participants are women aged 20 to 89 who have completed treatment for breast cancer and are prescribed exerc…
Phase: NA • Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
Double injection may double pain relief after lung surgery
Symptom relief Not yet recruitingThis study tests whether giving a nerve block at two rib levels instead of one can better control pain after video-assisted thoracoscopic surgery for lung cancer. Eighty-eight adults scheduled for lung surgery will receive either a standard single-point block or a two-point block…
Sponsor: Shiyou Wei • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Digital Self-Care could ease lymphatic pain after breast cancer
Symptom relief Not yet recruitingThis study tests a digital behavioral program called The-Optimal-Lymph-Flow (TOLF Self-Care) for breast cancer survivors who experience lymphatic pain—a common, often painful condition that can lead to chronic lymphedema. The program teaches self-care skills to promote lymph flow…
Phase: NA • Sponsor: University of Missouri, Kansas City • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Acupuncture may offer Drug-Free relief for breast cancer Survivors' lingering symptoms
Symptom relief Not yet recruitingThis study tests whether acupuncture can help breast cancer survivors who are on hormone therapy and still dealing with pain, fatigue, and poor sleep. Researchers will give a standardized acupuncture treatment and measure changes in these symptoms. The goal is to find out if acup…
Phase: PHASE3 • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Zapping the brain to ease chemo nerve pain: a new hope for breast cancer survivors
Symptom relief Not yet recruitingThis study tests two types of theta burst stimulation, a non-invasive brain stimulation technique, to relieve chronic nerve pain caused by chemotherapy in breast cancer survivors. Forty participants will receive both types of stimulation at different times, with brain scans used …
Phase: NA • Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
New drug cocktail aims to stop Chemo-Linked nausea before it starts
Symptom relief Not yet recruitingThis study tests whether a combination of two drugs, fosrolapitant and palonosetron, can prevent nausea and vomiting caused by antibody-drug conjugates (ADCs) in cancer patients. Participants are adults with malignant tumors who have never received ADCs before and are about to st…
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
New radiation method aims to shrink large tumors
Symptom relief Not yet recruitingThis pilot study tests whether adding a specialized radiation technique called Lattice Radiation Therapy (LRT) to standard palliative radiation can safely shrink large tumors (at least 4.5 cm) in adults. The study will enroll 25 people with various cancers who are already schedul…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New device aims to speed up breast reconstruction surgery
Symptom relief Not yet recruitingThis study tests a device called ORASIS, which helps keep the surgical area clean during DIEP flap breast reconstruction. The device automatically removes fluid and smoke, so the surgeon can work without pausing. The trial will include 30 women who have had a mastectomy and are g…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New radiation technique aims to shield airways and preserve lung function
Symptom relief Not yet recruitingThis trial compares standard radiation therapy with a new method that specifically avoids damaging small airways in the lungs. The goal is to see if this airway-sparing approach helps patients with stage III non-small cell lung cancer retain better breathing function after treatm…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Virtual reality tested as a calming tool during chemo
Symptom relief Not yet recruitingThis study tests whether using a virtual reality headset with guided imagery—like calming nature scenes and breathing exercises—can reduce pain, anxiety, and fatigue in women with breast cancer during chemotherapy. Participants are randomly assigned to either receive VR-guided im…
Phase: NA • Sponsor: Thoalfokar Mohammed Al-Obaidi • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Could a comfort cart make cancer treatment easier for seniors?
Symptom relief Not yet recruitingThis study will test a comfort menu and cart for older adults (60+) receiving cancer treatment at a hospital in Brazil. The cart offers items like blankets, pillows, and hygiene kits to improve comfort. Researchers will compare patient and staff experiences before and after the c…
Phase: NA • Sponsor: Hospital Sirio-Libanes • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Can a supplement beat cancer fatigue? new trial aims to find out
Symptom relief Not yet recruitingThis study tests whether a dietary supplement called Redsenol-1 Plus can safely reduce fatigue in adults who have had cancer treatment. 72 participants will take either the supplement or a placebo for 12 weeks. The main goal is to see if fatigue levels improve, as measured by a s…
Phase: NA • Sponsor: Canada Royal Enoch Phytomedicine Co., Ltd. • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Can a morning light session boost immunotherapy? small trial aims to find out
Symptom relief Not yet recruitingThis pilot study tests whether using bright light therapy for an hour each morning, delivered through an iPad app, is tolerable for people with advanced melanoma or non-small cell lung cancer who are about to start immunotherapy. The idea is that synchronizing the body's internal…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Can a drug stop muscle loss in lung cancer? new trial aims to find out
Symptom relief Not yet recruitingThis early-stage trial tests whether the drug ponsegromab can help adults with advanced non-small cell lung cancer who are losing muscle mass (cachexia). About 80 participants will receive either ponsegromab or a placebo. The study measures changes in muscle size and physical fun…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New program aims to ease financial burden for cancer patients
Symptom relief Not yet recruitingThis study tests a simple screening tool to identify cancer patients struggling with medical costs. Those who screen positive will be connected to financial counseling and resources at their hospital. The goal is to make it easier for patients to afford their care and reduce fina…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Phone app aims to ease anxiety in breast cancer survivors
Symptom relief Not yet recruitingThis study tests a smartphone app that offers short mental health exercises for breast cancer survivors. The exercises target negative thinking, coping skills, and relaxation. The goal is to see if using the app for 8 weeks reduces anxiety and depression symptoms. The study will …
Phase: NA • Sponsor: University of Virginia • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Warm blankets during surgery may shield Seniors' brains
Symptom relief Not yet recruitingThis study tests whether keeping older patients (65+) at a slightly higher body temperature (36.8°C) during major cancer surgery can reduce the risk of delayed neurocognitive recovery—a kind of short-term confusion or memory decline that can happen after surgery. About 1,500 part…
Phase: NA • Sponsor: Peking University First Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could a cannabis gummy be the key to better sleep for cancer patients?
Symptom relief Not yet recruitingThis study tests whether a cannabis gummy can improve sleep and quality of life in 50 cancer patients who have trouble sleeping. Participants will either take the gummy or receive usual care for 5 weeks. The goal is to see if the gummy is safe and helps with sleep, while also che…
Phase: PHASE1, PHASE2 • Sponsor: Theodore Brasky PhD • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could a painless electrical patch help cancer patients sleep better after surgery?
Symptom relief Not yet recruitingThis study tests whether a non-invasive technique called transcutaneous electrical acupoint stimulation (TEAS) can prevent or treat sleep problems after cancer surgery. TEAS uses mild electrical pulses on specific points on the skin, based on acupuncture, without needles. The tri…
Phase: NA • Sponsor: Second Hospital of Shanxi Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New rehab plan aims to get breast cancer patients moving faster after surgery
Symptom relief Not yet recruitingThis study will test a structured early rehabilitation program for women who have had breast cancer surgery. The program includes education, gentle exercises starting the day after surgery, and home-based workouts with monitoring. Researchers want to see if it is safe and helps w…
Phase: NA • Sponsor: Marta Aguilar-Rodriguez • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
AI coach may soothe radiation skin burns in breast cancer patients
Symptom relief Not yet recruitingThis study tests whether an artificial intelligence-powered digital education program can reduce the severity of radiodermatitis (skin irritation from radiation) and improve quality of life in women with breast cancer. 38 patients will be randomly assigned to either receive the A…
Phase: NA • Sponsor: Ataturk University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Sophrology: a new way to calm radiation anxiety?
Symptom relief Not yet recruitingThis study tests whether sophrology, a relaxation technique using gentle movements, breathing, and positive visualization, can reduce anxiety in cancer patients undergoing radiation therapy. Fifty-four adults with various cancers will be offered sophrology sessions during their t…
Phase: NA • Sponsor: Clinique Pasteur Lanroze • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Fasting during immunotherapy: a new way to boost treatment?
Symptom relief Not yet recruitingThis study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…
Phase: NA • Sponsor: West Virginia University • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Exercise program aims to boost quality of life in young cancer patients
Symptom relief Not yet recruitingThis study tests whether a supervised strength training program can improve quality of life, physical function, and mental health in children with cancer. Twenty participants under 18 who are currently on treatment or dealing with after-effects will do two 50-minute sessions per …
Phase: NA • Sponsor: University of Salamanca • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Simple breathing and muscle relaxation may ease chemo sleep woes
Symptom relief Not yet recruitingThis study tests whether learning progressive muscle relaxation and deep breathing exercises can improve sleep for cancer patients receiving chemotherapy. About 40 adults aged 40-60 with poor sleep will be split into two groups: one gets relaxation training plus usual care, the o…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Smart device aims to boost lung recovery after cancer surgery
Symptom relief Not yet recruitingThis study tests a smart breathing exercise device for people recovering from lung cancer surgery. About 200 adults will either use the device for 30 days after surgery or receive standard care. The goal is to see if the device improves lung function, reduces shortness of breath,…
Phase: NA • Sponsor: Jianxing He • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Dance away chemo pain: new study tests fun exercise for nerve damage
Symptom relief Not yet recruitingThis study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New app aims to ease lung cancer treatment side effects at home
Symptom relief Not yet recruitingThis study tests a home-based app for lung cancer patients on combination drug therapy. The app helps patients track symptoms, get personalized advice, and receive nurse support during treatment breaks. Researchers will see if it reduces symptom burden and improves quality of lif…
Phase: NA • Sponsor: Feifei Huang • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Phone app aims to keep lung cancer patients moving during treatment
Symptom relief Not yet recruitingThis study tests whether a smartphone reminder app can help lung cancer patients stay physically active during radiation therapy. About 32 adults with lung cancer will use the app or standard care, and their daily step counts will be compared. The goal is to see if simple digital…
Phase: NA • Sponsor: University Hospital Schleswig-Holstein • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Can zoom workouts help older cancer patients in the countryside?
Symptom relief Not yet recruitingThis study tests whether a 12-week exercise program, delivered via Zoom, is practical and helpful for older adults (65+) with cancer who live in rural areas. Participants will do two supervised exercise sessions per week. The goal is to see if the program improves quality of life…
Phase: NA • Sponsor: University of Saskatchewan • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Spinal fluid may hold clues to breast cancer brain spread
Knowledge-focused Not yet recruitingThis study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Can AI craft the perfect exercise plan for breast cancer survivors?
Knowledge-focused Not yet recruitingThis study explores whether a large language model (AI) can generate personalized exercise prescriptions for people recovering from breast cancer surgery. Researchers will collect health and fitness data from 40 postoperative patients and use the AI to create exercise plans. Expe…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Could you help scientists unlock genetic cancer secrets?
Knowledge-focused Not yet recruitingThis study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
New program aims to bridge the trust gap between oncologists and latino patients
Knowledge-focused Not yet recruitingThis study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
New study aims to close racial gap in breast cancer screening
Knowledge-focused Not yet recruitingThis study tests whether a culturally tailored program can help Black women keep their mammogram appointments. About 176 women aged 40 and older who are scheduled for a screening mammogram will take part. The goal is to find better ways to reduce racial disparities in breast canc…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Vaping vs. smoking weed: which delivers THC faster?
Knowledge-focused Not yet recruitingThis study will compare how quickly and how much THC enters the blood when people vape THC liquids versus smoking cannabis. Forty healthy adults who already use both products will try each method in a random order. Researchers will measure THC levels, side effects, and puffing be…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Blood test may foretell Radiation's toll on the gut
Knowledge-focused Not yet recruitingThis observational study is investigating whether a blood marker called GLP-2 could help predict the risk and severity of acute radiation enteritis—a common and painful side effect of radiation therapy to the abdomen or pelvis. Researchers will measure GLP-2 levels in 50 adults b…
Sponsor: Wang Xinying • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
Knowledge-focused Not yet recruitingThis observational study follows Indian adults with resectable non-small cell lung cancer who are prescribed durvalumab as part of their routine care. The goal is to monitor how often patients experience serious side effects, including severe adverse events and other complication…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can better HER2 classification improve breast cancer care?
Knowledge-focused Not yet recruitingThis study looks at breast cancer tumors to understand HER2 levels, including low and ultra-low expressions, which may affect treatment choices. Researchers will examine tissue samples from 100 patients diagnosed in Sohag, Egypt, and compare HER2 status with other tumor features …
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New imaging study aims to unlock HER2 secrets in lung cancer
Knowledge-focused Not yet recruitingThis study uses a special PET scan to track a tracer called 89Zr-trastuzumab in people with advanced lung cancer that has HER2 changes. The goal is to see if the tracer builds up differently in tumors with HER2 mutations versus those with too much HER2 protein. About 20 adults wi…
Phase: PHASE1 • Sponsor: The Netherlands Cancer Institute • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can Immunotherapy's hidden toll on daily life be measured?
Knowledge-focused Not yet recruitingThis study follows 75 people with locally advanced non-small cell lung cancer who receive a year of adjuvant immunotherapy after chemoradiotherapy. Researchers will use questionnaires to track changes in quality of life and self-reported health from the start of immunotherapy to …
Sponsor: Göteborg University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Your gut bacteria might hold the key to lung cancer treatment
Knowledge-focused Not yet recruitingThis study is exploring whether the bacteria in your gut can predict how well a certain type of lung cancer responds to treatment. Researchers are following 100 people with stage II-IIIB non-small cell lung cancer who are receiving chemoimmunotherapy before surgery. The goal is t…
Sponsor: Guangdong Provincial People's Hospital • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Six-Gene clue: could a simple test forecast lung spread in breast cancer?
Knowledge-focused Not yet recruitingThis study is testing whether a six-gene risk score, calculated from a tumor tissue sample, can predict which women with early-stage breast cancer are more likely to develop lung metastasis. Researchers will follow 330 women aged 18 to 70 for up to 120 months, tracking lung metas…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Bone scans may reveal how breast cancer subtypes spread
Knowledge-focused Not yet recruitingThis observational study looks at whether different molecular subtypes of breast cancer—like Luminal A, HER2-enriched, and triple-negative—show distinct patterns of bone metastasis on bone scans. Researchers will compare imaging results from 100 adults with breast cancer to see i…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Radon education program aims to empower cancer survivors and their communities
Knowledge-focused Not yet recruitingThis study tests whether a short educational presentation about radon can improve knowledge and encourage testing among cancer survivors, their caregivers, and family members. Participants attend a single session, either in person or online, led by a study staff member. The goal …
Phase: NA • Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New study aims to unlock secrets of lung cancer drug through blood tests
Knowledge-focused Not yet recruitingThis study will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug tarlatamab. Researchers will analyze the samples to learn more about how the drug works, who might benefit most, and how to predict side effects like cytokine rele…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New digital tool aims to help young cancer patients discuss fertility and relationships with doctors
Knowledge-focused Not yet recruitingThis study tests a digital tool called ReSPECT that helps teens and young adults with cancer talk to their doctors about sexual and reproductive health. The tool includes a pre-visit checklist and an informational website. Researchers want to see if it is practical and helpful fo…
Phase: NA • Sponsor: Connecticut Children's Medical Center • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Cancer Patients' decisions shaped by drug benefit uncertainties, study finds
Knowledge-focused Not yet recruitingThis study investigates how providing information about uncertainties in new cancer drugs' benefits influences patients' hypothetical treatment decisions and perceptions. Researchers will present current or former cancer patients with a scenario about a new drug called Zenova, wh…
Phase: NA • Sponsor: London School of Economics and Political Science • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Texting cancer patients after hospital stays may cut ER visits
Knowledge-focused Not yet recruitingThis study tests whether sending automated messages to cancer patients after they leave the hospital can help them use urgent oncology care instead of the emergency room. About 200 patients will receive reminders via MyChart and text in English or Spanish. Researchers will track …
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Brazil tests lung cancer screening in smokers
Knowledge-focused Not yet recruitingThis study will screen 477 current or former smokers in Brazil for lung cancer using CT scans. It aims to see how often the scans give false alarms (false positives) in a region where lung infections are common. The goal is to improve screening accuracy and reduce unnecessary fol…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Does a Thigh-Based breast reconstruction hold up over time? a study investigates
Knowledge-focused Not yet recruitingThis observational study examines long-term quality of life and aesthetic outcomes in women who underwent breast reconstruction using a PAP flap — a technique that uses tissue from the inner thigh. Researchers will survey participants and analyze photos to understand satisfaction…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can a simple checklist boost recovery after cancer surgery?
Knowledge-focused Not yet recruitingThis pilot study tests whether surgeons will use a new set of timeline-specific guidelines designed to improve functional recovery after high-risk abdominal cancer surgery. Researchers will monitor how often surgeons follow the guideline in clinic. The goal is to see if such a to…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Lung cancer study seeks to map patient journeys
Knowledge-focused Not yet recruitingThis study reviews medical records of 250 people with advanced or metastatic non-small cell lung cancer that has a specific change in the EGFR gene. Researchers want to learn about patients' backgrounds, the treatments they receive, and how well those treatments work. The goal is…
Sponsor: Janssen-Cilag Farmaceutica Ltda. • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
Knowledge-focused Not yet recruitingThis study is looking at whether analyzing blood, urine, and stool samples can help predict which lung cancer patients are more likely to develop radiation pneumonitis—a type of lung inflammation—after receiving immunotherapy and radiation therapy. The researchers will collect sa…
Sponsor: HAN GUANG • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can immune profiling unlock the hidden stages of tuberculosis?
Knowledge-focused Not yet recruitingThis study aims to better understand tuberculosis (TB) across its entire spectrum—from early, symptom-free infection to active disease and after treatment. Researchers will recruit TB patients and their close contacts to analyze immune responses and identify biomarkers that could…
Sponsor: Irene Latorre Rueda • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Do cancer patients overestimate drug benefits? a trial puts communication to the test.
Knowledge-focused Not yet recruitingThis study asks whether adding overall survival data to standard progression-free survival information helps current or former cancer patients more accurately judge a new drug's survival benefit. Around 3,000 U.S. adults with a past or present cancer diagnosis will read about a h…
Phase: NA • Sponsor: London School of Economics and Political Science • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Morning or afternoon? new study tests if immunotherapy timing boosts cancer fight
Knowledge-focused Not yet recruitingThis study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Fitbit study aims to decode recovery after breast reconstruction
Knowledge-focused Not yet recruitingThis study will give 50 women a Fitbit Inspire 3 to wear before and after DIEP flap breast reconstruction surgery. Researchers will track steps, heart rate, and sleep, and compare that data with short questionnaires about recovery. The goal is to learn more about how patients rec…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Does breast cancer radiation harm a key immune gland? a study investigates
Knowledge-focused Not yet recruitingThis study looks at whether radiation therapy for breast cancer affects the thymus, a small gland in the upper chest that helps produce immune cells. Researchers will collect blood samples from young women aged 18 to 50 who are receiving radiation after breast cancer surgery, as …
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
A blood test may spot breast cancer's return before symptoms appear
Knowledge-focused Not yet recruitingThis observational study is testing whether a blood test called a liquid biopsy can provide useful information for people with early-stage breast cancer who are about to start treatment before surgery. The test looks for tiny fragments of tumor DNA circulating in the blood. Resea…
Sponsor: Spanish Breast Cancer Research Group • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
AI to predict heart damage from cancer treatments in major european study
Knowledge-focused Not yet recruitingThis study will collect data from up to 10,000 cancer patients across Europe to create better tools for predicting heart damage caused by certain cancer treatments. Researchers will use artificial intelligence alongside standard methods to develop risk scores that doctors can use…
Sponsor: University Hospital, Caen • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Can a smartwatch track how cancer treatment affects daily life?
Knowledge-focused Not yet recruitingThis study explores whether cancer patients undergoing treatment can use a smartwatch and smartphone surveys to report their quality of life and physical activity. Over 12 weeks, participants wear a smartwatch at least 10 hours a day and complete questionnaires at several time po…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
AI reads tumor slides: can computer scores predict who will do well?
Knowledge-focused Not yet recruitingThis study enrolls 1,000 adults with solid tumors, including breast cancer, who receive an AI-based pathology test as part of their routine care. Researchers will link the AI test results with short- and long-term health outcomes to see how well the scores predict prognosis and t…
Sponsor: Ataraxis AI, Inc. • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Can walking flush out hidden toxins? new study tests exercise against PFAS
Knowledge-focused Not yet recruitingThis study investigates whether different types of exercise can help middle-aged women reduce their body burden of PFAS (environmental chemicals) and improve muscle function. Participants will be assigned to either interval walking or high-intensity circuit training for six month…
Phase: NA • Sponsor: Poznan University of Physical Education • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Caregiver burden under the microscope: study links patient frailty to carer well-being
Knowledge-focused Not yet recruitingThis study looks at how the health of older adults with cancer affects the quality of life of the people who care for them. Researchers will follow 116 patient-caregiver pairs for six months, using questionnaires to measure caregiver well-being and patient frailty. The goal is to…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Glowing drug reveals why lung cancer immunotherapy fails
Knowledge-focused Not yet recruitingThis study tests a new way to see where an immunotherapy drug goes in the lungs of people with stage III lung cancer. Twenty participants will receive a small dose of a fluorescent version of the drug durvalumab, then have a special camera bronchoscopy to spot the drug in tumors …
Phase: PHASE2 • Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Breast reconstruction after mastectomy: which approach leads to happier patients?
Knowledge-focused Not yet recruitingThis study looks at how different types of bilateral breast reconstruction affect women's quality of life and satisfaction. Researchers will compare women who had preventive mastectomy (due to high risk) with those who had therapeutic mastectomy (due to cancer), and also consider…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Blood tests could reveal hidden resistance in breast cancer
Knowledge-focused Not yet recruitingThis study observes people with a common type of advanced breast cancer (HR+/HER2-) who are already on standard hormone therapy. Researchers use simple blood tests to look for changes in the ESR1 gene, which can make the cancer stop responding to treatment. By tracking these muta…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
AI chatbot aims to simplify cancer survivorship care
Knowledge-focused Not yet recruitingThis study tests an AI-powered chatbot that automatically creates personalized survivorship care plans for adult cancer survivors. The chatbot uses information from electronic health records to generate a plan and answer patients' questions about it. Researchers want to see if th…
Phase: NA • Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Lab-Grown lung tumors could reveal why some drugs work and others fail
Knowledge-focused Not yet recruitingThis study takes leftover tumor samples from people with EGFR-mutant non-small cell lung cancer and grows them in the lab as cell cultures and organoids. Researchers will test different anti-EGFR drugs on these models to see which ones work best for each type of mutation and expl…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Exercise after breast cancer: which workout best boosts healing muscle signals?
Knowledge-focused Not yet recruitingThis pilot study looks at how different resistance training routines change levels of myokines—molecules released by muscles during exercise—in women who have finished breast cancer treatment. Participants will be assigned to one of three exercise regimens (conditioning, strength…
Phase: NA • Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
HIV and cancer: study seeks to uncover hidden risk factors
Knowledge-focused Not yet recruitingThis study looks at how certain cancers develop in people with HIV and what factors might increase their risk. Researchers will analyze medical data from 1,000 HIV-positive adults to track which types of cancer occur most often and why. The goal is to improve early detection and …
Sponsor: Shenzhen Third People's Hospital • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
EU-Wide survey aims to uncover hidden gaps in mental health support for cancer patients
Knowledge-focused Not yet recruitingThis study uses online surveys to explore whether cancer patients and their family members across the European Union have equal access to mental health screening and psychological support. Researchers will analyze responses from 2,000 participants to identify disparities, barrier…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Smartwatch data could help predict cancer outcomes
Knowledge-focused Not yet recruitingThis study collects health data from Apple Watches and iPhones of 1,200 cancer patients to build a research database. The goal is to see if wearable data like activity and heart rate can help personalize cancer prognosis and treatment. Participants must have an Apple Health app a…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
AI could outshine standard tumor measurements to predict survival
Knowledge-focused Not yet recruitingThis study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Study probes whether tracking everyday chemical exposures could transform breast cancer prevention
Knowledge-focused Not yet recruitingThis study investigates whether adding environmental exposure risk assessments to standard care is useful and acceptable for women at average or high risk of breast cancer, as well as those diagnosed with early-onset breast cancer. Researchers will survey patients and providers a…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
AI tool aims to predict breast cancer drug success, sparing patients unnecessary side effects
Knowledge-focused Not yet recruitingThis study is developing an AI tool that analyzes tumor images, proteins, and patient data to predict whether a person with advanced HER2-positive or low-expression breast cancer will benefit from the targeted drug T-DXd. The goal is to avoid giving ineffective treatment, which c…
Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Yale launches massive blood repository to unlock cancer secrets
Knowledge-focused Not yet recruitingThis study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Can a chemo combo without anthracyclines still beat breast cancer?
Knowledge-focused Not yet recruitingThis study looks at how well a chemotherapy and immunotherapy combination works for early triple-negative breast cancer when the usual anthracycline drugs are left out. The researchers are focusing on patients who cannot take anthracyclines due to previous treatment, older age, o…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
4D MRI scans could reveal hidden clues about heart disease and cancer
Knowledge-focused Not yet recruitingThis study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…
Sponsor: Ulsan University Hospital • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Lung cancer drug interaction study aims to uncover safe dosing
Knowledge-focused Not yet recruitingThis phase 1 trial investigates how HS-10504, an experimental drug for EGFR-mutant non-small cell lung cancer, changes the way the body processes midazolam, a common sedative. About 24 patients with advanced lung cancer who have stopped responding to standard EGFR-targeted therap…
Phase: PHASE1 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Blood test may reveal hidden cancer spread without scans
Knowledge-focused Not yet recruitingThis study is testing whether a blood test can locate where colorectal cancer has returned or spread after surgery. Researchers are analyzing genetic markers in the blood to build a model that predicts whether a recurrence is local or distant. The goal is to improve early detecti…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Your voice in the tumor board: study tests if patient reports lead to better cancer treatment
Knowledge-focused Not yet recruitingThis study will include about 2,748 people with breast, gynecologic, or pancreatic cancer. Researchers want to see if adding patient-reported outcomes—like symptoms, preferences, and travel distance—to tumor board discussions helps doctors make better treatment decisions. The goa…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Could Breast-Conserving surgery be safe for women with multiple tumors?
Knowledge-focused Not yet recruitingThis study looks at whether breast-conserving surgery (removing only the tumor, not the whole breast) is safe for women diagnosed with multifocal or multicentric breast cancer—meaning they have two or more tumors in one breast. Researchers will follow 100 adult women for at least…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Could your body shape predict radiation accuracy?
Knowledge-focused Not yet recruitingThis study looks at whether a person's body composition—like muscle mass and body fat—affects how accurately they are positioned during radiation therapy. Researchers will measure body composition in 120–150 cancer patients before and during treatment, and track daily positioning…
Sponsor: Shijiazhuang People's Hospital • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Blood test could reveal how lung cancer evolves during treatment
Knowledge-focused Not yet recruitingThis study uses blood tests (liquid biopsies) to track how small cell lung cancer changes during chemotherapy and immunotherapy. Researchers will analyze DNA from blood samples taken before, during, and after treatment in 50 patients. The goal is to understand why some cancers be…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can exercise help cancer patients? new study aims to find out
Knowledge-focused Not yet recruitingThis study will survey 370 adult cancer patients about their knowledge, attitudes, and practices regarding physical exercise. The goal is to understand why many patients don't exercise enough and what barriers they face. Results will help create better exercise programs and possi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Simple blood test could guide breast cancer treatment
Knowledge-focused Not yet recruitingThis study looks at whether a blood test can predict how well the drug deruxtepruzumab works in people with advanced breast cancer that has low or ultra-low levels of a protein called HER2. Researchers will track cancer cells and HER2 levels in the blood of 100 patients during tr…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Cancer combo therapy under the microscope: real-world study launched
Knowledge-focused Not yet recruitingThis study will observe 200 cancer patients who are already receiving immunotherapy (immune checkpoint inhibitors) along with radiotherapy. Researchers want to see how long the cancer stays under control and how patients fare overall, in everyday clinical practice rather than a s…
Sponsor: Sichuan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New study aims to unlock secrets of breast cancer return
Knowledge-focused Not yet recruitingThis study follows 100 women whose breast cancer has come back after a mastectomy. Researchers will track their health for at least three years to understand what factors affect survival and how different standard treatments work. No experimental drugs are given; the goal is to l…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Blood test may reveal if breast cancer treatment is working
Knowledge-focused Not yet recruitingThis study looks at whether tracking tumor DNA in the blood (ctDNA) can help doctors see how well breast cancer treatment is working before surgery. It will include 186 people with stage II-III HER2-positive or triple-negative breast cancer. Researchers will take blood samples at…
Sponsor: Federico II University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can storytelling and support groups break the stigma around cancer in rwanda?
Knowledge-focused Not yet recruitingThis study looks at how common stigma is for breast and cervical cancer patients, caregivers, and community health workers in Rwanda. It also tests a program called RISE that includes resilience training, support groups, and videos of cancer survivors to see if it can reduce stig…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Too much info weighing on cancer patients? new study investigates
Knowledge-focused Not yet recruitingThis study looks at how feeling overwhelmed by information and dealing with symptoms affects the sense of empowerment in 300 adult cancer patients getting outpatient chemotherapy. Researchers will use surveys to measure information overload, symptom severity, and empowerment leve…
Sponsor: University of Yalova • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Mind over money: study tests if resilience shields cancer survivors from financial toll
Knowledge-focused Not yet recruitingThis study looks at how financial stress from cancer treatment affects quality of life in breast cancer survivors, and whether personal strengths like resilience and posttraumatic growth can soften that blow. About 160 women will fill out surveys before, during, and after chemoth…
Sponsor: Okayama University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study aims to predict immunotherapy success in cancer patients
Knowledge-focused Not yet recruitingThis study will collect data from 500 cancer patients who are about to start immunotherapy. Researchers want to build a tool that can predict survival outcomes based on factors like combination treatments. The goal is to help doctors and patients make more informed decisions abou…
Sponsor: Sichuan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
Knowledge-focused Not yet recruitingThis study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Mapping the hidden toll: how breast cancer brain metastases affect daily life
Knowledge-focused Not yet recruitingThis study follows 200 adults with stage 4 breast cancer that has spread to the brain or spinal lining. Participants fill out questionnaires about their symptoms, thinking abilities, and physical function over time. The goal is to track how symptoms change and how treatments affe…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Body clock check: a simple swab may guide immunotherapy timing for lung cancer
Knowledge-focused Not yet recruitingThis study explores whether a hair follicle or cheek swab can accurately measure a person's internal body clock (circadian rhythm) in patients with advanced lung cancer receiving immunotherapy. Researchers will use a new tool called TimeTeller to analyze gene activity from these …
Sponsor: Laura Longshaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Could probiotics help breast cancer patients keep their strength?
Knowledge-focused Not yet recruitingThis study looks at whether changes in gut bacteria are linked to cancer-related weight and muscle loss (cachexia) in women with breast cancer who receive care at home. About 140 participants will provide blood, stool, and urine samples and answer questionnaires. Some will take a…
Phase: NA • Sponsor: Fondazione ANT Franco Pannuti ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive study aims to standardize lung cancer testing across labs
Knowledge-focused Not yet recruitingThis study involves 3,400 people with advanced non-small cell lung cancer to see if a new test for a protein called TROP2 works consistently across different laboratories. The goal is to ensure that doctors can reliably use this test to guide treatment decisions. Participants pro…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to predict survival in respiratory care units
Knowledge-focused Not yet recruitingThis study will collect data from 624 patients in respiratory intermediate care units (RICUs) across Catalonia to build a model that predicts 30-day survival. Researchers will also test an artificial intelligence approach and create a quick app for doctors. The goal is to better …
Sponsor: Hospital Universitari de Bellvitge • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Anesthesia choice may affect immune system during breast cancer surgery
Knowledge-focused Not yet recruitingThis study will enroll 56 women with breast cancer to see if two different regional anesthesia techniques (paravertebral block vs. erector spinae plane block) cause different immune responses during surgery. Participants will receive one of the two blocks along with general anest…
Phase: NA • Sponsor: Clinical Hospital Center Rijeka • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
AI reads CT scans to predict which lung nodules turn cancerous
Knowledge-focused Not yet recruitingThis study will develop an artificial intelligence model that uses a patient's series of CT scans over time to predict whether a lung nodule will grow or become cancerous. Researchers will analyze scans from nearly 5,000 people to train the AI to recognize different growth patter…
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Timing is everything: new study seeks best sequence for brain metastases treatment
Knowledge-focused Not yet recruitingThis observational study looks at adults with non-small cell lung cancer that has spread to the brain. Researchers want to see if getting radiation and immunotherapy 30 days apart or closer together changes how long the brain tumors stay stable and how long patients live. Partici…
Sponsor: Xiangya Hospital of Central South University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Tracing a cancer Drug's journey through the body
Knowledge-focused Not yet recruitingThis study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Omega-3s may reshape breast cancer fats, new study hopes to prove
Knowledge-focused Not yet recruitingThis study tests whether taking omega-3 supplements before surgery can change the types of fats found in breast tumors. About 35 adults with early-stage breast cancer will take the supplement for 4 to 28 weeks while also receiving standard cancer treatments. The goal is to see if…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Can a 4-Week mediterranean diet boost breast cancer surgery recovery?
Knowledge-focused Not yet recruitingThis pilot study will test whether a 4-week Mediterranean diet program is practical and acceptable for women newly diagnosed with breast cancer before they have surgery. Twenty post-menopausal women with stage I-III breast cancer will receive all their meals and snacks. The main …
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study aims to spot hidden cancer spread in lobular breast cancer
Knowledge-focused Not yet recruitingThis study will test whether whole-body MRI scans and blood tests for tumor DNA can better detect cancer progression in a type of breast cancer that is often missed by standard scans. Researchers will follow 43 people with metastatic invasive lobular carcinoma for up to 30 months…
Phase: NA • Sponsor: KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Leftover immunotherapy may boost chemo: new study investigates timing
Knowledge-focused Not yet recruitingThis study looks at how much pembrolizumab (an immunotherapy drug) remains in the blood after treatment ends and whether that affects how well chemotherapy works later. Researchers will follow 110 people with non-small cell lung cancer or head and neck cancer who have stopped pem…
Phase: PHASE4 • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New imaging registry aims to sharpen cancer treatment precision
Knowledge-focused Not yet recruitingThis study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …
Sponsor: Mark C Burgmans, MD PhD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Can exercise become a standard part of cancer treatment? new study aims to find out
Knowledge-focused Not yet recruitingThis study looks at the best ways to add supervised exercise programs into standard cancer care. Researchers will track how often doctors refer patients to exercise and how many patients take part. The goal is to see if this approach is practical and helps improve patients' physi…
Phase: NA • Sponsor: Melanie Keats • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New scanner may spot hidden breast cancer metastases
Knowledge-focused Not yet recruitingThis study aims to see if taking PET/CT scans later after injection of a special tracer (18F-Fluoroestradiol) can better detect breast cancer that has spread to the liver or abdomen. Researchers will use a new, more sensitive scanner that allows for later imaging, which may impro…
Phase: NA • Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Scientists use MRI to create Custom-Fit breast implants
Knowledge-focused Not yet recruitingThis study aims to use MRI and 3D images from 25 women who have had or will have a mastectomy (breast removal) to develop a computer model for a customizable breast implant called MyBREAST One. The goal is to create implants that are tailored to each person's body. This is an ear…
Sponsor: HELMo Link asbl • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New study aims to unlock genetic secrets of lung cancer spread
Knowledge-focused Not yet recruitingThis study looks at a specific type of lung cancer called lung adenocarcinoma and how it can spread through tiny air spaces in the lungs. Researchers will collect tumor and healthy tissue samples from 140 patients to find genetic markers that might predict this spread. The goal i…
Sponsor: Universidade Nova de Lisboa • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Massive study to uncover cancer Therapy's hidden toll on fertility
Knowledge-focused Not yet recruitingThis large observational study will follow 4,000 young cancer survivors (ages 15-39) across Europe to understand how different cancer treatments impact fertility, hormone function, and pregnancy outcomes. Researchers will also evaluate the safety and success of fertility preserva…
Sponsor: Karolinska Institutet • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Major study to uncover cancer Treatment's hidden toll on fertility
Knowledge-focused Not yet recruitingThis study will follow 3,000 young women (ages 15-39) with cancer to understand how treatments like chemotherapy and immunotherapy impact their fertility, pregnancy outcomes, and quality of life. Researchers will also look at the safety and success of fertility preservation metho…
Sponsor: Karolinska Institutet • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Can more screening catch lung cancer sooner? big study aims to find out
Knowledge-focused Not yet recruitingThis study looks at medical records of 3,000 adults with lung cancer to see if the stage at diagnosis is shifting to earlier, more curable stages. Researchers will track how often cancer is found through screening programs, chest X-rays, or heart scans. No new treatments or tests…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Artificial intelligence could spot hidden cancer spread before It's too late
Knowledge-focused Not yet recruitingThis study will test an artificial intelligence system designed to give early warning of cancer spreading to other parts of the body. Current imaging can only see larger tumors, but this AI analyzes routine scans and patient data to detect signs of microscopic spread. Researchers…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC